Stockwinners Market Radar for November 04, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:16 EDT Cathie Wood's ARK Investment bought 102.5K shares of Facebook on Thursday

18:44 EDT NYC mayor-elect Adams says he will take first 3 paychecks in bitcoin - New York City Mayor-Elect Eric Adams said in a Tweet: "In New York we always go big, so I'm going to take my first THREE paychecks in Bitcoin when I become mayor. NYC is going to be the center of the cryptocurrency industry and other fast-growing, innovative industries! Just wait!" The tweet was in response to Miami Mayor Francis Suarez, who said he will take his next paycheck "100%" in bitcoin. Reference Link

18:24 EDT Norwegian Cruise Line CEO: Bookings are strong, excited about the future - In an interview on CNBC's Mad Money, Frank Del Rio said Norwegian took a hard line on Covid vaccinations, but it has worked out great. The back half of 2022 is going to be good he added, and 2023 "looks terrific." The company has pricing power due to incredible demand, he noted. Sales in the ship's boutiques are at records. "We're on the right side of the pandemic now," he said.

18:05 EDT My Size enters cooperation pact, resolves litigation with Custodian Ventures - My Size announced that it has entered into a cooperation agreement with Custodian Ventures and its affiliates. In addition, My Size announced that it is seeking to enhance shareholder value by evaluating acquisition opportunities while refocusing on the commercialization of MySizeID. Custodian Ventures has agreed to conclude its public campaign and withdraw its director candidates for election at the company's 2021 Annual Meeting of Stockholders. The company has agreed to withdraw the lawsuit it previously filed in the United States District Court for the Southern District of New York against Custodian Ventures and certain stockholders.

17:55 EDT GAP Airports reports October traffic up 3.4% - For October 2021, the total number of terminal passengers at GAP's 12 Mexican airports increased by 3.4%, compared to the same period of 2019. Los Cabos, Puerto Vallarta and Tijuana airports presented an increase in passenger traffic of 27.5%, 17.8% and 15.1%, respectively, while the Guadalajara airport presented a decrease of 7.8%.

17:45 EDT Lionsgate exploring potential alternatives for STARZ, including spin-off - Lionsgate said in a regulatory filing that, on November 2, 2021, the company's Board of Directors authorized the company's management team to explore potential capital markets alternatives for its Media Networks business including, but not limited to, a full or partial spin-off, split-off, issuance of a tracking stock or other transactions. There can be no assurance that any such transaction will be announced or completed, and completion of any such transaction would be subject to various terms, conditions and regulatory approvals, as well as approval of the company's Board of Directors.

17:41 EDT Peloton says Tread could be bigger category than bike

17:38 EDT Capital Bancorp initiates 5c per share quarterly dividend - The dividend is payable on November 30, 2021 to shareholders of record as of November 15, 2021.

17:33 EDT GoPro says fundamentally has strong demand - Says retail drove outperformance in Q3. Says has supply to meet demand in Q4. Says targeting long-term margins 40%-43%. Says best selling GoPro is highest priced model. Says subscriber retention healthy. Comments taken from Q3 earnings conference call.

17:28 EDT Peloton still sees being adjusted EBITDA profitable in 2H22 - Says overall traffic for bike price cut below forecasts. Says underestimated impact of economic reopenings. Says committed to making material improvements to cost structure to become net cost neutral in 2023. Says more focused on profit dollars than margin percentage.

17:25 EDT Brookdale Senior Living expects Q4 adjusted EBITDA $35M-$40M

17:22 EDT Uber CEO says pricing will likely ease up in Q4 - Comments taken from Q3 earnings conference call Q/A.

17:20 EDT Loyalty Ventures to replace Applied Optoelectronics in S&P 600 at open on 11/9 - Loyalty Ventures (LYLT) will replace Applied Optoelectronics (AAOI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, November 9. S&P MidCap 400 constituent Alliance Data Systems Corp. (ADS) is spinning off Loyalty Ventures in a transaction expected to be completed on November 8. Applied Optoelectronics is no longer representative of the small-cap market space.

17:18 EDT BioLife Solutions names Troy Wichterman as CFO, Roderick de Greef as COO - BioLife Solutions announced changes to its executive management team, effective immediately. Troy Wichterman, BioLife's Vice President of Finance since 2019, has been promoted to CFO. Wichterman joined BioLife in 2015 as a financial analyst and was subsequently promoted to positions of increasing responsibility including oversight of the company's financial planning, analysis and SEC reporting. Prior to BioLife, he served in various financial positions at Ventas, Heitman and PricewaterhouseCoopers. Roderick de Greef, former CFO, has been named President and COO, postponing his previously announced retirement until early 2023. Rod has been with BioLife for more than 20 years serving both as a board member and executive leader and we greatly appreciate his decision to delay his retirement and take on this operations leadership role.

17:14 EDT Galapagos sees FY21 operational cash burn EUR 530M-EUR 570M - Previous outlook was EUR 580M-EUR 620M.

17:11 EDT MorphoSys presents interim results from M-PLACE study with felzartamab - MorphoSys AG presented interim results from the M-PLACE study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology on November 4-7. The poster entitled "Felzartamab in patients with anti-phospholipase A2 receptor autoantibody positive membranous nephropathy (MN): Interim results from the M-PLACE study" shows data from the ongoing Phase 1b/2a, proof of concept, open-label, multicenter study designed to assess the safety and efficacy of felzartamab in adults with high anti-PLA2R-positive MN, an autoimmune kidney disease and a leading cause of nephrotic syndrome in adults. Patients with high autoantibody titers are considered a population difficult to induce immunologic remission. The M-PLACE study included 31 patients with primarily medium or high levels of anti-PLA2R antibody titers at baseline and/or patients who were refractory to previous treatments. Of the 27 treated patients with evaluable results, 24 showed an initial rapid reduction of anti-PLA2R antibody levels one week after the first treatment. After 12 weeks of treatment, most patients showed a substantial reduction in autoantibody titer. More mature data from all patients will be obtained over the following months, including the complete urine protein: creatinine ratios for all patients, to evaluate if the observed immunological response is followed by a clinical response, the company said in a statement.

17:09 EDT Uber says Mobility recovery has reignited after soft period around Delta variant

17:08 EDT Shift Technologies co-CEO Toby Russell to step down, remain on board - Shift Technologies and its Board of Directors announced today that Toby Russell will be stepping down as Co-CEO on Feb. 1, 2022. Russell will continue to serve on the company's Board of Directors and as Strategic Advisor to the company following his transition. George Arison, Co-founder and Co-CEO, will serve as sole CEO, effective Feb. 1, 2022. As of Nov. 4, 2021, the majority of Russell's day-to-day operational responsibilities are transitioning to Shift's President, Jeff Clementz, who joined the company on Oct. 1, 2021 after a long career at Walmart and PayPal, and who reports to Arison. "It has been an incredible journey to take Shift from an idea to a publicly traded eCommerce leader," said Russell. "After leading six straight years of growth, I couldn't be more proud of the company we have built and the team we have assembled. This is the right time for me to transition to a Board and advisory role, allowing me to focus on my family, bringing my two daughters - who currently live on opposite coasts - together back in Virginia. I am extremely grateful for and confident in the outstanding team and culture we have built at Shift. The company is well positioned to rise to new heights with our extraordinary leadership team."

17:07 EDT Peloton says lower guidance due to supply chain issues, freight costs - Says modeling exit from COVID and massive growth from it would be a major task. Says teams have never seen a more complex operating environment in which to guide or expect results. Says have returned to presenting ranges amid uncertainty. Says visibility into future performance has become limited. Says original bike price reduction helped create shift in demand. Says supply chain crises and freight costs led to lower guidance. Says saw greater than expected tapering in retail visits in Q1. Says experienced greater than expected tapering in website traffic. Says hardware margins seeing near-term compression from supply chain and logisticis issues. Says while sales not meeting previous forecasts, third-party data suggests that the company can continue to increase market share. Says long-term thesis of fitness at home remains unchanged. Comments taken from Q1 earnings conference call.

17:07 EDT Uber CEO says Q3 Mobility saw margins comparable with 2019 highs - Says number of active drivers is up 65% since January and more than 20% since June. Says driver earnings are at all time highs. Comments taken from Q3 earnings conference call.

17:02 EDT Longboard Pharmaceuticals reports Q3 EPS (38c), consensus (48c) - At September 30, Longboard's cash, cash equivalents and short-term investments were approximately $112.6M and approximately 16.9M shares of Longboard voting and non-voting common stock were outstanding. "This quarter we successfully completed the MAD portion of our Phase 1 clinical trial for our lead asset, LP352, and we look forward to initiating our first clinical trial in patients with severe and refractory epilepsies next quarter. We are collaborating with a world-class CRO and have commenced key activities for trial readiness and site activation. We continue to engage with thought leaders, advocacy groups and caregivers in order to prioritize enrollment optimization, and most importantly, the best outcome for patients living with these devastating diseases," stated Kevin Lind, Longboard's president and CEO. "For LP143 and LP659 we look forward to sharing additional preclinical data that support the scientific rationale for our initial areas of focus as we approach IND submissions for each program in 2022."

16:58 EDT T2 Biosystems names Brett Giffin as chief commercial officer - T2 Biosystems announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Giffin will join the company's executive leadership team and lead our commercial growth initiatives with direct responsibility for global sales, marketing, service, and customer support functions. Giffin replaces Anthony Pare, who recently accepted a role as CEO at BioPorto A/S.

16:57 EDT Entravision acquires 365 Digital, terms not disclosed - Entravision announced that it has acquired 365 Digital, a digital advertising solutions company headquartered in South Africa. This investment provides Entravision with a geographic foothold in Africa, as the Company looks to expand its breadth of digital services to new emerging markets. Headquartered in Cape Town, South Africa, 365 Digital maintains exclusive sales representations with TikTok, the leading destination for short-form mobile video and brand solutions, and Anzu, an in-game advertising platform, and is also the authorized representative for Triton Digital, a leader in the digital audio streaming and podcasting market. 365 Digital also offers end-to-end digital publisher solutions for premier South African publishers, including a proprietary digital ad network. "We are very pleased to announce our acquisition of 365 Digital and our continued global expansion," said Walter Ulloa, Chairman and Chief Executive Officer of Entravision. "365 Digital's strong management team will fit seamlessly into Entravision's growing digital business, and we look forward to leveraging their regional expertise and existing big tech representations to scale Entravision's digital platform across Africa. This acquisition fully aligns with our vision to position Entravision as a global digital marketing solutions powerhouse, serving brands and local leaders with advanced branding, performance and programmatic needs. We've strategically expanded our geographic footprint into some of the fastest growing marketplaces across the globe and, as reported today in our third quarter 2021 earnings press release, digital revenue increased nearly 10 times more than the prior-year period."

16:54 EDT Barstiool's Dave Portnoy calls Business Insider story 'hit piece' - Barstool's Dave Portnoy called the story from Business Insider a "hit piece" and responded via a video posted on Twitter. Reference Link

16:53 EDT GoPro sees FY22 revenue growing from increase in units, ASP - The company said "We expect increasing direct-to-consumer and subscription revenue to have a positive impact on gross margin and EPS."

16:52 EDT PureCycle Technologies names Lawrence Somma as CFO - PureCycle Technologies (PCT) announced that Lawrence Somma has joined the innovative plastics recycling company as the next CFO. Somma will lead PureCycle's financial strategy as the company seeks to transition to a revenue-generating growth business. Most recently, Somma spent eight years at LyondellBasell Industries (LYB), where he served as vice president of finance strategy and transformation for two years and vice president, corporate treasurer for six years.

16:50 EDT Cognex raises quarterly dividend 8% to 6.5c per share - Cognex announced that the company's Board of Directors declared a quarterly cash dividend of $0.065 per share, payable on December 3, 2021 to all shareholders of record at the close of business on November 19, 2021. This dividend represents an increase of $0.005 per share, or 8%, over the $0.06 per share dividend paid in the prior quarter.

16:48 EDT Chuy's says still not in position to provide Fy21 guidance due to pandemic - Chuy's states: "Due to the ongoing uncertainty around the magnitude and duration of the COVID-19 pandemic, the Company is not in a position to provide full fiscal 2021 financial guidance, except the Company anticipates: Net capital expenditures (net of tenant improvement allowances) to be approximately $15 to $17 million. Restaurant pre-opening expenses to be approximately $2 million vs. approximately $2 to $3 million. An effective annual tax rate of approximately 14% to 16%."

16:46 EDT Chuy's announces new $50M stock buyback

16:39 EDT Velodyne Lidar names Theodore Tewksbury CEO - Velodyne Lidar announced the appointment of Theodore "Ted" L. Tewksbury, Ph.D. as Chief Executive Officer, effective November 10, 2021. Tewksbury most recently served as Chief Executive Officer of Eta Compute. "We are pleased to welcome Ted to the Velodyne team. Ted's extensive leadership experience in addition to engineering expertise, make him an ideal candidate to lead Velodyne as we continue to lead the lidar industry with the most cutting-edge products and scalable manufacturing capacity," said Michael Dee, Chairman of the Velodyne Board of Directors. "Innovation and execution are our most important priorities and Ted's direct experience designing and manufacturing leading-edge technologies makes him a natural complement to Velodyne's world-class technology development and engineering team. Velodyne is far and away the market leader, having sold over 15,000 sensors in the last 12 months with the widest product range in the industry. We are confident that under his leadership, Velodyne is poised to continue expanding its global footprint and drive long-term value for all shareholders."

16:38 EDT Expedia: Covid recovery 'somewhat bumpy'

16:35 EDT EOG Resources declares $2.00 per share special dividend - EOG's board of directors declared a special dividend of $2.00 per share on EOG's Common Stock. The dividend is payable December 30, 2021 to stockholders of record as of December 15, 2021. "EOG has now committed to return $2.7 billion of cash to stockholders in 2021, representing approximately 30% of expected 2021 discretionary cash flow," the company said.

16:35 EDT EOG Resources ups regular dividend 82% to indicated annual rate of $3.00/share - EOG said the Board of Directors declared a regular dividend of 75c per share on EOG's Common Stock. The dividend is payable January 28, 2022 to stockholders of record as of January 14, 2022. The new dividend represents a $3.00 per share indicated annual rate, an 82% increase from the previous level. "The annual cash commitment towards the dividend is $785 million higher and reflects EOG's low cost of supply, robust cash flow generation and strong balance sheet. A growing, sustainable dividend is the company's primary mode of returning cash to shareholders. EOG has a long track record of delivering against this objective as the company has never suspended or reduced its regular dividend," the company said.

16:33 EDT Expedia: ex-Delta, Q3 would have been most profitable quarter ever - Comments taken from Q3 earnings conference call.

16:26 EDT Carvana says revenue growth in Q4 to be closer aligned with retail unit growth - The company states: "We continue to see exceptional demand and expect retail units sold to be governed primarily by our operational capacity. We expect revenue growth in Q4 to be more closely aligned with retail unit growth than it was in Q3. We expect total GPU to be in the low-to-mid $4,000s for the full year, marking our 8th consecutive year of substantial gains. We expect to see a seasonal pattern in total GPU in the fourth quarter, with Q4 lower than Q3. Finally, we plan to continue to invest in the business both to catch up with current demand and to prepare for growth in 2022 and beyond, leading to a seasonal sequential increase in SG&A per retail unit in Q4 and close to breakeven EBITDA margin for the full year."

16:24 EDT Peloton down 23% after reporting Q1 earnings, giving Q2, FY22 guidance

16:16 EDT AnaptysBio sees ending 2021 with $600M in cash - The company said: "Following the anticipated closing of the Sagard royalty monetization transaction by the end of 2021, we anticipate ending 2021 with approximately $600 million in cash and will continue to operate in a capital-efficient manner." Additionally, it said: "We anticipate top-line data in Q4 2021 from our ongoing Phase 1 healthy volunteer trial of rosnilimab, our wholly-owned PD-1 agonist antibody, designed to assess the safety, pharmacokinetics and pharmacodynamics of rosnilimab in single and multiple ascending dose cohorts. We plan to initiate a randomized, placebo-controlled Phase 2 clinical trial of rosnilimab in alopecia areata in Q4 2021. We are advancing ANB032, our wholly-owned BTLA modulator antibody, in a healthy volunteer Phase 1 single and multiple ascending dose clinical trial where top-line data is anticipated during the first half of 2022."

16:14 EDT Square sees Seller to deliver 'strong gross profit growth' in October - Square said: "In October, we expect Seller to deliver strong gross profit growth year over year and on a two-year CAGR basis. Seller GPV is expected to be up 42% year over year in October, and the two-year CAGR is expected to be up 24%, a slight improvement compared to 23% growth in the third quarter on a two-year CAGR basis. GPV growth trends continued to vary by region, product, and vertical, depending primarily on differences in the timing and phases of reopenings. In October, we expect Cash App to deliver strong gross profit growth year over year and on a two-year CAGR basis driven by growth in monthly actives, engagement across our ecosystem, and inflows into Cash App."

16:13 EDT Verastem has cash runway until at least 2024 - The company states: "With the proceeds and expected milestones and royalties from the sale of COPIKTRA, Verastem Oncology expects that it has a cash runway until at least 2024 to deliver on the current programs for VS-6766 and defactinib, including expenditures and development in LGSOC and KRAS mutant NSCLC. Verastem Oncology expects its 2021 annual operating expenses to be approximately $55-60 million."

16:08 EDT Uber sees Q4 gross bookings $25B-$26B, adjusted EBITDA $25M-75M

16:06 EDT Uber reports Q3 gross bookings up 57% y/y to $23.1B - Gross Bookings grew 57% year-over-year to $23.1 billion, or 53% on a constant currency basis, with Mobility Gross Bookings of $9.9 billion and Delivery Gross Bookings of $12.8 billion. Trips during the quarter grew 39% YoY to 1.64 billion, or nearly 18 million trips per day on average.

16:05 EDT Covetrus sees FY21 organic net sales growth 5%-6% - See sFY21 adjusted EBITDA $245M-$255M.

16:02 EDT OpenText announces renewal of share repurchase plan - The company announced the renewal of its share repurchase plan and that it intends to purchase in open market transactions, from time to time over the next 12 months, if considered advisable, up to an aggregate of $350M of its common shares.

16:00 EDT HyreCar expands partnership with AmeriDrive, Cogent Bank - HyreCar Inc. announced an expanded strategic partnership to significantly increase car supply in key markets on the HyreCar platform. The formal partnerships include AmeriDrive Holdings, a leading automotive mobility fleet manager, and Cogent Bank's Specialty Finance Group. Cogent has agreed to expand its lending capacity so that AmeriDrive can continue to build its fleet exclusively on the HyreCar platform. This fleet will include electric vehicles in key markets which builds on a strategic commitment of HyreCar to provide EV cars to rideshare and delivery drivers in the United States. "HyreCar's expanded relationship with AmeriDrive and Cogent Bank utilizes an established platform to help our partners grow their business," said Joe Furnari, CEO of HyreCar. "This expanded partnership will continue to fortify HyreCar's ecosystem that serves the gig economy on a national scale and will help us meet our goals to add and utilize over 50,000 cars by 2025 on HyreCar's platform."

15:18 EDT Delta reports 450% rise in international point-of-sale bookings after U.S. opens - Delta stated in a post to its corporate news hub: "As the U.S. reopens to fully vaccinated international travelers, Delta Air Lines is reuniting families and friends who have been kept apart for the past 20 months. In the six weeks since the U.S reopening was announced, Delta has seen a 450% increase in international point-of-sale bookings versus the six weeks prior to the announcement. Many international flights are expected to operate 100% full on Monday, Nov. 8, with high passenger volume throughout the following weeks. The reopening positively impacts customers in 33 countries around the world, with Delta serving 10 of these nonstop and more via its global hubs in connection with its partners, including Air France, KLM and Virgin Atlantic." Reference Link

13:18 EDT Estee Lauder exec O'Hare sells 1,961 class A shares - In a regulatory filing, Estee Lauder EVP of Global Human Resources Michael O'Hare disclosed the sale of 1,961 class A common shares of the company on November 3 at a price of $335 per share.

13:12 EDT Novartis reports iptacopan meets primary endpoints in Phase 2 G3G study - Novartis announced that a Phase 2 study of investigational iptacopan - a first-in-class, oral, selective factor B inhibitor - in patients with C3 glomerulopathy, or C3G, met primary endpoints in both patient cohorts. The data were presented at the American Society of Nephrology, or ASN, 2021 Annual Meeting. In the final analysis from the open-label, two-cohort Phase 2 study, patients were treated with 200mg of iptacopan twice daily for 12 weeks, in addition to background therapy. Patients in cohort A - 16 with C3G, but who have not had a kidney transplant - showed a significant 45% reduction in proteinuria compared to baseline, as measured by 24-hour urinary protein to creatine ratio. Patients in cohort B - 7 whose C3G had returned following a kidney transplant - showed significantly reduced C3 protein deposits compared to baseline, as measured by C3 deposit score from kidney biopsy. Additionally, both cohorts of this Phase 2 study showed strong and sustained inhibition of alternative complement pathway activity and normalization of serum C3 levels over 12 weeks. Iptacopan showed a favorable safety and tolerability profile in the Phase II final analysis, with no serious adverse events suspected to be related to iptacopan. Reference Link

12:14 EDT Fluor-led JV awarded contract to install grinding mill in Indonesia - Fluor Corporation announced that its joint venture with Petrosea - Fluor Petrosea Joint Organization - has been selected by PT Freeport Indonesia to install a new grinding mill at its Grasberg copper and gold mining district in Papua, Indonesia. Fluor booked its undisclosed portion of the contract in the third quarter of 2021. FPJO will construct a third semi-autogenous grinding mill adjacent to the existing milling facilities as the mining district continues to ramp up underground production primarily from the Deep Mill Level Zone and Grasberg Block Cave mines following completion of mining in the open pit in 2019. With the additional SAG mill, the milling capacity will be approximately 240,000 tonnes per day. "Fluor has built several expansions at Grasberg as well as other major projects in Indonesia since the 1980s," said Tony Morgan, president of Fluor's Mining & Metals business. "We value the trust we have earned over the decades with the Freeport team and are proud to expand our global footprint in the industry as a solutions provider for the global copper demand."

12:02 EDT Inotiv shareholders approve acquisition of Envigo - Inotiv announced that, at a special meeting of shareholders held today, Inotiv shareholders approved, among other matters, an increase in the company's authorized shares and the issuance of Inotiv common shares to the stockholders and option holders of Envigo RMS Holding Corp. in connection with the acquisition of Envigo by merger of Envigo with a newly formed, wholly owned subsidiary of the company. Approval of these matters by the Inotiv shareholders was a condition to the closing of the acquisition. Robert Leasure, Jr., the company's President and Chief Executive Officer, commented, "We look forward to completing the Envigo transaction, as approved by shareholders, which we believe will position the combined organization as the preeminent, full-spectrum discovery-to-approval solution for drug developers. We are excited about the benefits and value this transaction is expected to bring to our customers, employees and shareholders." The acquisition of Envigo is expected to close in one or two business days, subject to satisfaction of closing conditions.

12:01 EDT Schweitzer-Mauduit falls -13.0% - Schweitzer-Mauduit is down -13.0%, or -$4.93 to $33.01.

12:00 EDT Lightspeed falls -30.7% - Lightspeed is down -30.7%, or -$30.43 to $68.54.

12:00 EDT Maxar Technologies rises 18.1% - Maxar Technologies is up 18.1%, or $4.90 to $31.95.

11:15 EDT FuelCell says will work with White House to create clean hydrogen infrastructure - FuelCell said via Twitter that, "FuelCell Energy will work with @POTUS and @ENERGY in support of the #BBB framework to create clean hydrogen infrastructure. We support the #BuildBackBetterAct and Infrastructure Bill." Reference Link

10:39 EDT Karyopharm says 33% of MF patients saw spleen volume reduction in study - Karyopharm Therapeutics announced that an abstract detailing new data from a Phase 2 study evaluating selinexor in patients with myelofibrosis previously treated with JAK inhibition has been selected for an oral presentation at the upcoming American Society of Hematology meeting. The results were based on the open label, prospective, investigator-initiated single center study in adult patients with primary or secondary myelofibrosis with resistance or intolerance to JAK inhibitor therapy. Selinexor was administered orally at a dose of 80mg or 60mg once weekly to 12 patients. The primary endpoint of the study is to assess the efficacy of selinexor on spleen volume reduction. Median duration of prior JAK inhibitor therapy was 22 months and 11 out of 12 patients had MF refractory to ruxolitinib. As of the data cutoff, the median duration of treatment was 36 weeks. In the nine patients who were on treatment for over 24 weeks, spleen volume reduction of greater than or equal to 25% and 35% occurred in four and three patients, respectively. Overall, selinexor demonstrated single-agent activity with sustained spleen responses in patients with JAK inhibitor refractory MF and long-term administration of selinexor was well tolerated, Karyopharm said in a statement.

10:00 EDT Manitowoc falls -11.7% - Manitowoc is down -11.7%, or -$2.69 to $20.32.

10:00 EDT Quotient Technology falls -19.8% - Quotient Technology is down -19.8%, or -$1.34 to $5.43.

10:00 EDT Lumen rises 16.2% - Lumen is up 16.2%, or $1.97 to $14.15.

10:00 EDT NeoPhotonics rises 34.1% - NeoPhotonics is up 34.1%, or $3.92 to $15.45.

09:52 EDT Cassava says 'Journal of Neuroscience' found no evidence of data manipulation - Cassava Sciences announced that it has been informed by the "Journal of Neuroscience" that there is no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer's disease. The peer-reviewed article was co-authored by scientists and academic collaborators for Cassava Sciences and is foundational to simufilam, the company's lead drug candidate for the proposed treatment of Alzheimer's disease. In August 2021, a law firm representing anonymous short sellers submitted a Citizen Petition to the U.S. Food and Drug Administration that alleges, among other things, data manipulation in Western blots in a science article published by the Journal of Neuroscience in July 2012. In response to this and similar on-line allegations, the Journal of Neuroscience requested raw data for the article, including images of original, uncropped Western blots. Having received that data and completed its review, the Journal of Neuroscience states: "No evidence of data manipulation was found for Western blot data." One human error that does not impact data conclusions was identified, a duplicated panel in Figure 8B of the article, and the publisher is expected to print a correction. The Journal of Neuroscience authorized Cassava Sciences to share a statement on this matter: "The Journal of Neuroscience follows COPE - Committee on Publication Ethics - guidelines and takes any claims of misconduct very seriously. In response to allegations of data manipulation in JNeurosci 2012;32:9773-9784 the Journal requested raw data, including images of original, uncropped Western blots. The Journal determined that there was one duplicated panel in Figure 8 and a Corrigendum was requested and will be printed. No evidence of data manipulation was found for Western blot data." In October 2021, a second Citizen Petition was submitted to FDA by an individual unknown to Cassava Sciences. This second petitioner "is requesting the FDA for approval of simufilam and immediate initiation of Phase 4 trials for further efficacy, safety assessment and, most critically, to address one of the greatest needs in modern medicine." The FDA has not engaged with the company regarding either Citizen Petition, Cassava stated. Remi Barbier, President and CEO, said: "I've never doubted the integrity of our people or science. We remain focused on conducting a Phase 3 clinical program of simufilam in people with Alzheimer's disease. It's an important endeavor, notwithstanding pundits who may be louder than they are learned. We'll stay the course until our job is done."

09:47 EDT Kellogg 'a bit more cautious' on volume in Q4, given current labor negotiations

09:47 EDT Quotient Technology falls -22.6% - Quotient Technology is down -22.6%, or -$1.53 to $5.24.

09:47 EDT GoDaddy rises 13.1% - GoDaddy is up 13.1%, or $8.83 to $76.04.

09:47 EDT NeoPhotonics rises 32.7% - NeoPhotonics is up 32.7%, or $3.77 to $15.29.

09:43 EDT Kellogg sees Q4 tax rate higher than FY's projected rate of 22%

09:43 EDT Kellogg seeing no moderation of supply shortages

09:41 EDT Co-Diagnostics' Logix Smart Covid-19 2-gene test approved in U.K. - Co-Diagnostics announced that its Logix Smart SARS-CoV-2 2-Gene multiplex test has been validated according to the United Kingdom Health Security Agency's Medical Devices Regulations 2021 and is available for sale in the UK under the Regulation. Co-Diagnostics' test has completed the validation required by the CTDA and received approval to be sold according to the amended Regulation, and has been validated for use with several sample types, including saliva, the company said in a statement. "We are pleased that our 2-gene multiplex SARS-CoV-2 test has been approved for sale according to the UK's high standard of quality and performance," remarked Dwight Egan, CEO of Co-Diagnostics. "Since the pandemic began, we have been on the forefront of providing gold-standard PCR solutions across the world, including Europe."

09:40 EDT Adagene announces publication of two abstract at ASH annual meeting - Adagene announced publication of two abstracts featuring preclinical data from its expanding pipeline in advance of the 63rd ASH Annual Meeting & Exposition. The preclinical results show compelling differentiation of ADG153, an anti-CD47 SAFEbody and ADG152, a CD20xCD3 POWERbody integrating the company's proprietary bispecific T-cell engager platform with SAFEbody masking technology. "We are excited to share the first preclinical results from our ongoing evaluation of ADG152 and ADG153, which are two novel programs emerging from our deep, broad, and differentiated pipeline," said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. "The known challenges of targeting CD47 - specifically, the need for a Fc dependent efficacious antibody without triggering on-target off tumor liabilities, including binding to red blood cells or showing significant antigen sink in healthy cells - and those of bispecific CD3 TCEs - a clinically validated, powerful modality with cytokine release syndrome limiting their utility - are the ideal problems for our AI-powered platform and antibody engineering teams to overcome in a tailor-made manner." Dr. Luo continued, "We look forward to presenting more detailed results during the ASH sessions, including new data from our ADG153 program, with one of the first ever anti-CD47 antibodies of the IgG1 isotype on track for clinical development. Additionally, ADG152 is the first novel bispecific TCE that incorporates our SAFEbody anti-CD3 antibody which has a low binding affinity and demonstrates strong anti-tumor activity while maintaining an impressive control of cytokine release in vivo, an outstanding issue facing many TCEs in clinical development. We are extremely encouraged by the data supporting differentiation of these candidates, which collectively showcase how we are on the forefront of antibody discovery and development to address patient needs."

09:38 EDT Cellectis announces release of abstracts at ASH showcase - Cellectis announced the release of two abstracts, which were accepted for presentation at the 63rd American Society of Hematology, ASH, Annual Meeting taking place from December 11-14, 2021. The Company will present updated preliminary clinical data from its BALLI-01 clinical trial in patients with relapsed/refractory B-cell acute lymphoblastic leukemia, B-ALL, and preclinical data for TALGlobin01 for patients with HbSS Sickle Cell Disease, SCD. Cellectis Poster Presentations: BALLI-01 investigating UCART22 product candidate in R/R B-ALL: The abstract includes updated preliminary data from the Phase I, open-label, dose-escalation BALLI-01 study in patients with R/R B-ALL from the first cohort of patients who received UCART22 after FCA lymphodepletion. The data show that the addition of alemtuzumab to fludarabine and cyclophosphamide was well tolerated, deepened host T-cell depletion and promoted CAR-T cell expansion. UCART22 is a novel and genetically modified allogeneic T-cell product manufactured from healthy donor cells. TALGlobin01; an autologous ex vivo TALEN(R)-edited CD34+ HSC therapy for the treatment of Sickle Cell Disease: Sickle cell disease is a common inherited disease that stems from a single mutation in the HBB gene. The data that will be presented are the first demonstration that TALEN-based engineering could be used to correct the mutation in the beta-globin gene of homozygous sickle cell anemia patient-derived hematopoietic stem and progenitor cells. The data showed high level of hemoglobin A expression, reversion of sickling phenotype, the capacity of TALGlobin01 edited cells to engraft in vivo, and a low level of off-target cleavage. Collectively, the data demonstrate high efficiency and safety of TALEN treatment in HSPCs and positioned it as the best-in-class gene editing technology for gene therapy product development.

09:36 EDT Wallbridge Mining commences trading on OTCQX - Wallbridge Mining Company is pleased to announce that its common shares will commence trading today on the United States OTCQX Best Market. The Company's common shares are to be quoted on the OTCQX under the symbol "WLBMF" and will also continue to trade on the Company's principal market, the Toronto Stock Exchange, under the symbol "WM".

09:36 EDT Athenex presents interim data from ANCHOR study of KUR-502 - Athenex announced data from the ANCHOR Phase 1 study of KUR-502 to be highlighted in a poster presentation at the 63rd American Society of Hematology Annual Meeting and Exposition, being held from December 11th to December 14th, 2021. The data demonstrates that allogeneic CD19 CAR-NKT cells are well-tolerated and can mediate objective responses in B-cell relapsed/refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia patients even at the low doses tested. The primary and secondary objectives of the phase I dose-escalation trial are to assess safety and anti-tumor activity of allogeneic NKT cells engineered to co-express a CD19-specific CAR, IL-15, and shRNAs targeting HLA class I and II molecules. Patients received a single infusion of 107 or 3107 allogeneic CAR-NKT cells per square meter of body surface area following lymphodepleting conditioning with cyclophosphamide/fludarabine. Four patients with relapsed/refractory B-cell non-Hodgkin's lymphoma were enrolled on DL 1 and DL 2, and 1 patient with relapsed acute B-lymphoblastic leukemia was enrolled on DL 1. Allogeneic CAR-NKT cells were manufactured from the leukapheresis product of one HLA-unmatched healthy individual and cryopreserved. The most common adverse effects observed were nausea and grade 3-4 hematologic toxicities related to the lymphodepletion chemotherapy. There were no early adverse events attributable to the cellular product except grade 1 cytokine release syndrome in one patient. Of the 4 NHL patients, 2 had a partial response and 1 had a CR. The ALL patient achieved a CRi and showed no evidence of leukemia by morphology, flow cytometry, or next-generation sequencing at 4 weeks. In vivo expansion of donor-derived NKT and CAR-NKT cells was detected in the peripheral blood of NHL-4 and ALL-1 that peaked at 1 week post-infusion in both cases as determined by flow cytometry and qPCR. While CAR-NKT cells were not detected in the peripheral blood of the first three NHL patients beyond three hours post-infusion, they were found in tumor tissues collected from the two biopsied NHL patients at up to 5 weeks post infusion. In patient NHL-2, a 2000-fold expansion of recipient NKTs with a skewed T cell receptor repertoire was also observed; this population peaked at 6 weeks post-treatment and remain elevated through 12 weeks.

09:35 EDT ViacomCBS says Paramount+ deal available to all T-Mobile subscribers - Says continues to believe in benefit of wholesale streaming deals. Says DOJ claims on Simon & Schuster sale "without merit." Plans to "vigorously contest" the lawsuit. Says seeing some advertising softness due to supply chain issues.

09:35 EDT Kellogg seeing acute shortages in labor, recruiting 'continuously'

09:34 EDT Splash Beverage Group's TapouT beverage gets rebrand - Splash Beverage Group announced a rebranding of its TapouT performance hydration-recovery drink to launch January 2022. As the $7 billion performance drink market continues to gain momentum, the rebrand is intended to broaden consumer market appeal and help secure large distribution networks for TapouT into expanded retail and shelf space. apouT is an international lifestyle brand that has been growing beyond its core position at the forefront of Mixed Martial Arts since its inception in 1997. Rebranded TapouT features a fully bilingual label with all text in both English and Spanish, appealing to Spanish-speaking bi-lingual consumers who have been a large segment of TapouT's customer base due to interest in MMA, as well as changing demographics in the U.S. The bottle's ergonomic shape is designed for active lifestyle consumers to enjoy while working out or just simply on the go. TapouT's appetizing flavor and clean formula, feature a unique balance of ingredients for both hydration and recovery, are called out on the new label including: zero sugar; no artificial sweeteners, colors or flavors; number of calories; 5 electrolytes; 6 B vitamins; and 3 antioxidants.

09:33 EDT Liquid Media's iNDIEFLIX appoints Christine Laskin as COO - Liquid Media Group has promoted Christine Laskin to the position of Chief Operating Officer. With the company for more than one year to date, Laskin has been successfully applying her wealth of growth-oriented experience to help iNDIEFLIX flourish. Her earlier background includes significant success working on asset management teams in the US and internationally as well as managing sales and product teams.

09:31 EDT Global Blood Therapeutics announces six data presentations at ASH meeting - Global Blood Therapeutics announced that six abstracts related to its sickle cell disease programs, including data from the growing body of real-world evidence on Oxbryta tablets and new data on GBT's pipeline, will be presented at the 63rd American Society of Hematology, ASH, Annual Meeting & Exposition. The meeting is taking place online and in person at the Georgia World Congress Center in Atlanta, Georgia from December 11-14, 2021. The three Oxbryta analyses provide greater insight into its efficacy and safety in both the real-world and long-term clinical trial settings: An analysis of nearly 2,700 patients ages 12 years or older from the Symphony Health claims database who initiated Oxbryta treatment between November 2019 and March 2021 demonstrated that, in real-world practice, Oxbryta increased hemoglobin, consistent with the results of the Phase 3 HOPE Study. These data show statistically significant reductions in transfusions, vaso-occlusive crises, and all-cause and VOC-related hospitalizations after Oxbryta use. An evaluation of data from an open-label extension of the Phase 3 HOPE Study demonstrated that long-term use of Oxbryta is safe, well tolerated, and has a durable effect in reducing anemia and hemolysis in patients with SCD. Data from the Retrospective Study to Evaluate Outcomes in Patients with Sickle Cell Disease Treated with Oxbryta, the first multicenter, retrospective study to examine the real-world effectiveness of Oxbryta, showed the treatment was associated with increased Hb levels and decreased hemolytic markers. The safety data are consistent with those from the Phase 3 HOPE Study of SCD patients ages 12 years and older. Data presented from two key Phase 1 studies from GBT's R&D pipeline in SCD include: An analysis of a Phase 1 study of GBT021601 will highlight data in both healthy volunteers and a cohort of six adults with SCD. Single ascending doses in healthy volunteers and single doses of GBT601 in patients with SCD were well tolerated in healthy volunteers and patients with SCD. In addition, multiple-dose data will be presented and will help to evaluate GBT601's potential as a best-in-class, oral, disease-modifying therapy. An analysis of a Phase 1 study of inclacumab, GBT's fully human P-selectin monoclonal antibody in development for the reduction of VOCs in SCD patients, displayed a well-tolerated safety profile for up to 29 weeks following a single dose of 20 or 40 mg/kg in healthy subjects. An additional abstract features data from a natural history cohort of pediatric patients with SCD: An analysis of a natural history cohort of pediatric SCD patients showed an inverse relationship between Hb level and transcranial Doppler velocity in patients with SCD, supporting the beneficial effect of higher Hb levels in SCD patients. TCD is a validated screening tool to identify pediatric SCD patients at risk of cerebrovascular events.

09:31 EDT Ford commences cash tender offers for up to $5B in debt securities - Ford Motor announced that it has commenced cash tender offers to purchase its outstanding 9.000% Securities due April 2025, 9.625% Securities due April 2030, 7.45% GlobLS due July 2031, 9.980% Debentures due February 2047, 8.900% Debentures due January 2032, 8.500% Securities due April 2023, 7.500% Debentures dueAugust 2026, 7.125% Debentures due November 2025, 6.625%, Debentures due October 2028 and 6.375% Debentures due February 2029, subject to an aggregate tender cap. The company will only accept for purchase securities in the tender offers up to an aggregate principal amount of all series of securities that does not exceed $5B, Ford noted.

09:30 EDT Sysorex acquires balance of data center, increases ethereum mining capacity - Sysorex announced that it has completed the acquisition of the remaining 50% of the upstate New York data center that houses the majority of its approximately 500 Gigahash of compute capacity, which is online, continuously mining Ethereum and securing the Ethereum Blockchain. Up North Hosting LLC, a data center owner and operator in upstate New York, was previously jointly owned by businesses controlled by Sysorex's recently appointed Chief Technology Officer, cryptocurrency industry veteran Brian Raymond, and Sysorex. Sysorex now owns 100% of the data center, which offers the Company immediate access to additional capacity to expand its mining operations. The purchase also included approximately 1000 GPUs, which presently increases mining capacity by approximately ten percent. The purchase price paid by Sysorex for the balance of the data center and GPUs was $1,000,000 and 1,000,000 shares of restricted Sysorex common stock.

09:29 EDT IGM Biosciences expects to end 2021 with over $200M in cash, investments - IGM reiterates its previously issued financial guidance expecting full year GAAP operating expenses to be between $175 million and $185 million including estimated non-cash stock-based compensation expense of approximately $25 million. IGM expects to end 2021 with a balance of over $200 million in cash and investments.

09:26 EDT Keros Therapeutics expects cash to fund operations into 4Q23 - Keros' cash and cash equivalents as of September 30, 2021 was $221.3 million compared to $265.9 million as of December 31, 2020. Keros expects that the cash and cash equivalents it had on hand at September 30, 2021 will fund its operating expenses and capital expenditure requirements into the fourth quarter of 2023.

09:21 EDT X4 Pharmaceuticals continues to expect cash to fund operations into Q4 2022 - X4 had $77.7M in cash, cash equivalents, and restricted cash as of September 30, 2021.

09:19 EDT Fifth Third announces second special payment to front-line employees - Fifth Third Bank, National Association, announced a special payment of $1,250 for full-time employees who have provided essential banking services to customers through the ongoing pandemic. It is the second time the Bank has recognized the work of these employees through a special payment program. "Our employees have gone above and beyond to ensure that we continue to meet the financial needs of our customers - whether it is by phone or in-person," said Tim Spence, president of Fifth Third Bancorp. "Our team has been working on site in our financial centers and office locations every day through the pandemic to serve customers. That has allowed us to keep 99% of our financial centers open. Our employees' efforts to keep customers at the center have been remarkable, and I'm pleased we are able to show our appreciation by providing this special payment."

09:19 EDT Affimed announce two poster presentations at ASH - Affimed announced that it will present two posters on its innate cell engagers at the 63rd American Society of Hematology Annual Meeting and Exposition, ASH. Details of presentations: Poster presentation 1: "AFM28, a Novel Bispecific Innate Cell Engager, Designed to Selectively Re-Direct NK Cell Lysis to CD123+ Leukemic Cells in Acute Myeloid Leukemia and Myelodysplastic Syndrome." AFM28 is a novel ICE, developed on Affimed's ROCK platform, specifically designed to address patient needs in Acute Myeloid Leukemia and other CD123+ myeloid malignancies, including high-risk Myelodysplastic Syndrome. Poster presentation 2: "Cryopreserved CAR-like NK Cells Pre-Complexed with the CD30/CD16A Bispecific Innate Cell Engager AFM13 for the Treatment of CD30+ Malignancies." AFM13 precomplexed NK cells maintained biological activity and potency after one cycle of freezing, demonstrating a promising approach to develop a cryopreserved off-the-shelf CAR-like NK cell immunotherapeutic. The high ADCC potency and efficacy of NK cells were maintained and a long cell surface retention, independent of CD16A polymorphism, has been demonstrated. The data to be presented support the development of a cryopreserved, off-the shelf ICE(R) / NK cell product, adding to the clinical utility of the treatment.

09:17 EDT LegalZoom curates network of small business service providers - LegalZoom.com has developed a curated, robust partner ecosystem of complementary, best-in-class services that provide small businesses with the right tools and services to manage and grow their business. Research conducted by LegalZoom shows that at the time of formation, among many vital services, 91% of new small businesses do not have payroll; 85% need payment processing solution; and 85% need a business banking account. As a trusted advocate for its customers, the LegalZoom partner ecosystem makes it easier for small business owners to select the right services for their particular needs at the appropriate time. Recent small business service providers that have partnered with LegalZoom on this initiative include Brex, Intuit QuickBooks and Square.

09:15 EDT AMD announces AMD Radeon PRO V620 GPU - AMD announced the AMD Radeon PRO V620 GPU, built with the latest AMD RDNA 2 architecture which delivers high-performance GPU acceleration for today's demanding cloud workloads including immersive AAA game experiences, intensive 3D workloads and modern office productivity applications at scale in the cloud.

09:15 EDT AMD announces continued collaboration with Microsoft Azure - AMD announced its continued momentum and collaboration with Microsoft Azure, who is offering the 3rd Gen AMD EPYC processor in the latest generation of Dasv5 and Easv5 Azure Virtual Machines. Azure is also introducing new confidential VMs, DCasv5 and ECasv5, which use the latest advanced security features available in 3rd Gen EPYC processors, including Secure Encrypted Virtualization-Secure Nested Paging. The new Azure confidential VMs, DCasv5 and ECasv5, the first EPYC processor-based confidential VMs at Azure and the first confidential VMs to use SEV-SNP, will enable customers to have the data in their security focused applications encrypted in use, in transit and at rest. The updated Dasv5 VMs, optimized for general purpose workloads, and the Easv5 VMs, optimized for memory-based workloads, deliver better price-performance for most general purpose and memory intensive workloads compared to prior EPYC processor-based Microsoft Azure VMs.

09:12 EDT BeiGene provides data on Brukinsa in CLL at ASH - BeiGene announced clinical results and real world data from its hematology program to be presented at the 63rd American Society of Hematology Annual Meeting and Exposition, including two oral presentations on the Phase 3 SEQUOIA trial comparing BRUKINSA, zanubrutinib, to bendamustine and rituximab B+R in patients with treatment-naive chronic lymphocytic leukemia, CLL, or small lymphocytic lymphoma, SLL. The ASH meeting will take place on December 11-14, as a hybrid event in Atlanta, GA and in a virtual format.

09:11 EDT Avidity Biosciences doses first person with antibody oligonucleotide conjugate - Avidity Biosciences announced that the first participants in the Phase 1/2 MARINA trial have been dosed with Avidity's lead Antibody Oligonucleotide Conjugates product candidate, AOC 1001, marking the first time a person has been dosed with an AOC. AOCs are designed to combine the proven technology of monoclonal antibodies with oligonucleotide therapies to access previously untreatable tissue and cell types. AOC 1001 is designed to address the root cause of DM1 by targeting DMPK, the disease-related mRNA. The AOC 1001 Phase 1/2 MARINA trial is enrolling adults with DM1.

09:10 EDT Oric Pharmaceuticals to present update on CD73 Inhibitor Progam - ORIC Pharmaceuticals announced a preclinical poster presentation at the American Society of Hematology Annual Meeting to be held December 11-14, 2021, in Atlanta, GA. Key points of the abstract include: In bone marrow aspirates from patients with relapsed or refractory multiple myeloma, an autologous ex vivo assay system comprising the multiple myeloma bone marrow milieu demonstrated that CD73-mediated adenosine activity suppressed the cytolytic activity of T-cells against tumor cells. CD73 inhibition triggered activation of plasmacytoid dendritic cells and stimulated T-cell activation in ex vivo assays of multiple myeloma bone marrow microenvironment. ORIC's small molecule inhibitor of CD73 overcame immune suppression and triggered significant lysis and cell death of multiple myeloma cells by autologous T-cells in the bone marrow microenvironment.

09:09 EDT Goodyear Tire announces collaboration with SARTA - The Goodyear Tire & Rubber Company and the Stark Area Regional Transit Authority, announced a collaboration to test intelligent tire sensors and prototype tires on SARTA's fleet of diesel and zero emission hydrogen fuel cell-powered buses. The intelligent tires leverage Goodyear's TPMS Plus on-vehicle sensors to send real-time data on tire conditions to the Goodyear SightLine mobility cloud. Using customizable algorithms, the data is quickly analyzed to deliver actionable insights on tire performance and potential vehicle issues so operators can seek proactive maintenance. The tests will help Goodyear evaluate the performance of TPMS Plus powered by Goodyear SightLine on HFC buses in daily public transit service, while also helping SARTA lower their operational costs, reduce fleet downtime and increase environmental benefits. Additionally, Goodyear is testing a prototype tire on SARTA's diesel and HFC buses to measure tread wear, rolling resistance and tire life. The data from these tests will help inform Goodyear's future tire designs for electric vehicles.

09:08 EDT Verisk Analytics launches cloud-based version of ISO Electronic Rating Content - Verisk has launched a new cloud-based version of its ISO Electronic Rating Content solution that can dramatically reduce the time and effort that commercial lines insurers spend updating rating content. The next generation of ERC is cloud-based and accessible via smart APIs. It is also significantly easier for insurers to use, integrate and test. The solution includes multiple deployment options to satisfy insurers' diverse needs, including: Rating-as-a-Service designed to eliminate insurers' need to host or maintain ISO content; Human-readable content designed for business analysts, effectively eliminating the need for insurers to analyze and interpret ISO content; Machine-readable content specifically tailored to be consumed into insurers' rating engines, a powerful option for those who wish to maintain the ISO content themselves; Validation tools designed to streamline insurers' testing efforts

09:07 EDT Zealand Pharma announces first patient dosed in Phase 1 trial of ZP8396 - Zealand Pharma announced that the first patient has been dosed in a Phase 1 clinical trial evaluating the amylin analogue, ZP8396 as a potential treatment option in obesity. The study is a single ascending, dose-escalation, safety and tolerability trial in healthy volunteers. "ZP8396 holds potential as a novel treatment option for obesity both as a monotherapy and in combination with other weight loss drugs, and the initiation of the Phase 1 clinical trial with ZP8396 is an important milestone for Zealand Pharma," said Adam Steensberg, Executive Vice President and Chief Medical Officer at Zealand Pharma. "We remain committed to utilizing our innovative peptide platform to develop medicines with the aim of addressing unmet needs for people with obesity and associated metabolic conditions."

09:06 EDT Nikola sees delivering pre-series Nikola Tre BEVs for use on public roads in Q4 - Nikola said it looks forward to achieving the following milestones in the fourth quarter of 2021: Deliver pre-series Nikola Tre BEVs for use on public roads hauling customer freight; Announce additional fleet testing dealers/customers; Purchase land for our first centralized hydrogen production hub facility and/or commercial on-site gaseous generation station; and announce additional hydrogen infrastructure/ecosystem partners.

09:05 EDT CME Group signs 10-year partnership with Google Cloud for derivatives market - CME Group (CME) and Google (GOOG) Cloud announced a 10-year strategic partnership to accelerate CME Group's move to the cloud. CME Group will migrate its technology infrastructure to Google Cloud beginning next year with data and clearing services, and eventually moving all of its markets to the cloud. With Google Cloud's technology, CME Group will co-innovate new products. By moving to the cloud, CME Group aims to streamline operations, optimize its IT infrastructure, and automate non-trading operations. To help facilitate the cloud migration for CME Group, Duffy has appointed Ken Vroman to a new role as Chief Transformation Officer. Google has also made a $1B equity investment in a new series of non-voting convertible preferred stock of CME Group.

09:05 EDT Super Group provides update on Betway European soccer deals - Super Group provided an update on Betway's European soccer sponsorship and partnership deals. Betway continues to make progress expanding its presence and commercial relationships across Europe's soccer leagues, recently renewing its sponsorship deal with Belgium's Croky Cup and becoming the official sports betting partner of the 11-time La Liga winner Atletico de Madrid in Spain. Furthermore, Betway executed an exclusive deal to become the sports betting partner of VfB Stuttgart, one of Germany's clubs. A digital advertising deal in Italy's Serie A completes a presence across the four biggest leagues in Europe. Meanwhile in Italy, Serie A, has applied digital billboard replacement technology, enabling Betway to have a presence in 45 fixtures during the season.

09:04 EDT Document Security's American Medical REIT acquires three more hospitals - DSS announced its majority-owned subsidiary, American Medical REIT, has acquired three hospitals located in Fort Worth, Texas, Plano, Texas and Pittsburgh, Pennsylvania. The aggregate purchase price for the Hospitals was $62M. The Hospitals are currently tenanted and operated by LifeCare Hospitals. The Hospitals acquired by AMRE are currently under an 18-year lease with eleven years remaining and an option to renew for an additional five years. The Hospitals have a total capacity of 195 hospital beds spanning a gross floor area of approximately 320,000 square feet. "These acquisitions represent a significant expansion of our real estate operations," stated Frank Heuszel, CEO of DSS. "While other areas within commercial real estate have been impacted by the ongoing pandemic, medical real estate has demonstrated considerable resiliency. With a now formidable foundation in place, we are in a great position to pursue further opportunities to expand AMRE as we continue to execute on our strategic growth plans."

09:04 EDT ALX Oncology to present early clinical data from ASPEN-02 - ALX Oncology Holdings announced the Company will be presenting early clinical data from ASPEN-02, its ongoing Phase 1/2 study evaluating evorpacept in combination with azacitidine for the treatment of myelodysplastic syndromes in a poster presentation at the 63rd American Society of Hematology Annual Meeting held December 11-14, 2021 in Atlanta, Georgia. As of July 15, 2021, 13 subjects with newly diagnosed higher risk or relapsed/refractory MDS were enrolled into phase 1 cohorts receiving escalating doses of evorpacept combined with standard doses of azacitidine. Of the 7 ND subjects, 4 had therapy-related MDS, and 5 had TP53 mutation with complex cytogenetics. Of the 6 R/R subjects, all had received at least one hypomethylating agent-based regimen. Among the 5 ND subjects evaluable for response, there were 2 subjects with cytogenetic response who met criteria for complete response subsequent to the date of this abstract, 1 subject with a best response of marrow complete response with hematologic improvement and 1 subject each with stable disease and progressive disease . Of the 4 ND subjects who were transfusion dependent at baseline, 2 achieved transfusion independence. Among the 5 R/R subjects evaluable for response, there were 2 subjects with a best response of mCR, 2 with SD, and 1 with PD. No dose-limiting toxicities were observed in any cohort and no maximum tolerated dose was reached. Additional results will be presented at the conference.

09:03 EDT Momentive announces availability of new GetFeedback capabilities - Momentive announced the availability of new GetFeedback capabilities that empower users to create and close feedback loops faster, allowing CX leaders to act upon meaningful insights with greater agility. With Embedded Listener, Program Accelerator, and new updates to the AI- and ML-powered Insights capabilities, CX professionals can drive better experiences across the entire customer lifecycle faster, iterate with ease, and deploy without requiring expensive consultants. The new capabilities are available now and include: Embedded Listener, an API that extends the GetFeedback platform into any offline, proprietary, or secure system, such as ATMs, smart TVs, airplane consoles, and more. This API allows users to adhere to organization-specific brand and security standards while gathering crucial customer feedback in touchpoints that were previously siloed from the holistic customer journey. Program Accelerator, now available in beta, a new capability that allows users to quickly build and launch turnkey programs based on CX best practices. Users can easily launch recurring programs at scale with pre-built survey and email templates in a matter of minutes. Users can then view aggregate or individual feedback, allowing them to understand customer feedback as a whole or to dive in deeper. The first program available in Program Accelerator is a relationship NPS sequencer, which helps users get a pulse on their customer base to uncover their advocates and detractors. The relationship NPS sequencer can be set up quickly and automatically send surveys throughout a selected time period, allowing users to properly measure and analyze the right metrics for their CX goals. Updates to Insights capabilities powered by AI and machine learning, including more in-depth open text analysis to easily parse through open text responses. Users can see the top-level sentiment of open text feedback as well as the top keywords and phrases. Users can also get even more granular with contextual analysis, now available in beta, on every phrase in each response, giving a more nuanced understanding of complex customer sentiment. Sentiment Analysis can now also be shown in 10 different languages and translated to English. As CX professionals scale their programs, Insights capabilities allow them to analyze ever-growing volumes of customer data quickly so they can take well-informed actions.

09:00 EDT GreenBox appoints Paul Levine as CEO of Coyni Stablecoin spinoff - GreenBox announced the appointment of Paul Levine to the position of Chief Executive Officer & Co-Founder for its Coyni Stablecoin spinoff company. Since 2010 Paul has served as President of Planet Payment an integrated digital payments provider, where he led the development and management of its direct acquiring cross-border eCommerce portfolio resulting in over $1 billion in processing volume.

08:57 EDT Ironwood in pact with COUR to commercialize CNP-104 to treat PBC in U.S. - Ironwood Pharmaceuticals announced that it is expanding its pipeline by entering into a collaboration and license option agreement with COUR Pharmaceutical Development Company, a biotechnology company developing novel immune-modifying nanoparticles to treat autoimmune diseases. This agreement gives Ironwood an option to acquire an exclusive license to develop and commercialize, in the U.S., COUR's investigational therapy CNP-104 , which if successful, could transform the treatment of Primary Biliary Cholangitis - otherwise known as PBC a rare autoimmune disease targeting the liver that affects an estimated 133,000 people in the U.S. Currently there is no cure, and medical care is focused on disease management. PBC can lead to irreversible damage and scarring of the liver tissue, ultimately requiring liver transplant. CNP-104 is being developed utilizing COUR's nanoparticle platform , a novel, proprietary system, which combines disease-specific pathogenic antigens with state-of-the-art pharmaceutical nanoparticles that mimic normal removal of dead or dying cells from the body. COUR's platform has shown proof of technology in clinical and preclinical settings, further demonstrating the opportunity for the platform to treat PBC. "Collaborating with COUR fits squarely within our business development framework and guiding principles; moving our strategy forward through expansion of our pipeline, leveraging our deep relationships with gastroenterologists and advancing innovation via highly differentiated opportunities like CNP-104," said Tom McCourt, president and chief executive officer of Ironwood. "COUR's expertise in immune reprogramming and Ironwood's development and commercial strength and reach in the GI disease area, will help introduce a potentially new therapy to patients in significant need of new options. This option agreement highlights our focus on prudently allocating capital to value enhancing opportunities while maintaining the flexibility to simultaneously execute on our other strategic priorities."

08:56 EDT iSun announces EV charging system selected for installation in Wisconsin - iSun announced that its iSun's Palm solar-powered EV charging system has been selected by an undisclosed party for a Wisconsin commercial EV charging installation.

08:55 EDT Canadian National announces purchase of Wabtec's battery-electric locomotive - CN announces its purchase of Wabtec's FLXdrive battery-electric freight locomotive, the first 100-percent battery heavy-haul locomotive for the region in support of CN's sustainability goals. This new technology is a component in achieving an effective transition to a lower carbon future. Pennsylvania's Department of Environmental Protection awarded financial support for the initiative under the Marine and Rail Freight Movers Grant Program. For its first battery-electric freight locomotive, CN plans to partner with Wabtec to put in service its FLXdrive technology, which can reduce fuel consumption and emissions by up to 30%. "As part of our sustainability strategy to reduce freight transportation emissions through innovation, we plan to continue to lead the sector by deploying low and no carbon technologies. At CN, we believe rail has a tremendous potential to reduce the environmental impact of transportation. As a mover of the economy, CN is committed to playing a key role in the transition to low-carbon economy." Jean-Jacques Ruest, President and Chief Executive Officer, CN

08:53 EDT Element Fleet introduces connectivity solutions ecosystem - Element Fleet Management announced the launch of Element Connectivity Solutions, the most diverse ecosystem of telematics products, services and strategic alliances in the fleet management industry. As part of this ecosystem, Element introduced two new products, QConnect and DriverCare CoPilot, for fleet operators seeking OEM-embedded and mobile device vehicle connectivity solutions. Element has long partnered with the leading pure-play telematics providers in the world, such as GEOTAB, to deliver fleet operators full-suite telematics with comprehensive rules-management and data collection. These continued partnerships and the introduction of QConnect and DriverCare CoPilot solutions to Element's expanding Connectivity Solutions ecosystem further enable fleet operators to choose connectivity solutions that truly meet their distinct data and analytics needs - no matter their hardware requirements, cost considerations or billing preferences.

08:53 EDT Harbor Custom Development board authorizes new stock repurchase program - The Board of Directors of Harbor Custom Development on November 3, 2021, approved a new stock repurchase program authorizing the repurchase of up to $5M worth of shares of common stock beginning November 22, 2021, and continuing through May 22, 2022. The amount of the repurchase program represents approximately 17% of the outstanding shares of the Company's common stock valued at the closing price on November 3, 2021. "The Board's decision to authorize a stock repurchase plan demonstrates their confidence in Harbor's business and growth opportunities we see over the long term," said Harbor President and CEO, Sterling Griffin.

08:50 EDT Wayfair sees Q4 capital expenditures $65M-$75M - Says there are near-term macro challenges. Says financial condition is strong. Says labor market is tight. Says inflation is rampant across the economy. Sees Q4 gross margin at low end of 27%-29% range. Sees Q4 adjusted EBITDA breakeven. Sees Q4 capital expenditures $65M-$75M. Comments and guidance taken from Q3 earnings conference call.

08:48 EDT PFSweb adds seventh Shiseido Americas brand to portfolio - PFS, a business unit of PFSweb, has launched a new U.S. order fulfillment operation for Drunk Elephant, a Shiseido Americas brand. This brand is among several in the Shiseido Americas portfolio serviced by PFS. PFS is providing the same group of services for Drunk Elephant as the previously announced Shiseido brands in support of the brand's direct-to-consumer eCommerce site. These services include warehouse management, inventory control, order fulfillment and returns management. The initial Drunk Elephant launch was in PFS' Dallas-area fulfillment center, with plans to expand to a multi-node operation at a second fulfillment center in 2021. Zach Thomann, EVP and President of PFS, commented: "The expansion of our relationship with Shiseido Americas highlights the success we have achieved since the partnership began in 2019. Multi-brand client portfolios gain efficiencies within our model as they add brands. The combination of those efficiencies and our expertise in health and beauty bring a powerful value proposition to the market. We look forward to helping Drunk Elephant expand their eCommerce strategy and initiatives."

08:47 EDT Bridgeline Digital, Luminos Labs partner to produce Optimizely B2C connector - Bridgeline Digital announced that their Hawksearch software team is working alongside Luminos Labs to produce an Optimizely B2C connector, available in the Optimizely marketplace in the coming weeks. Hawksearch is already integrated and in use by several customers with the Optimizely B2C platform. The connector adds to Hawksearch's library of integrations that include Salesforce B2B Commerce, Big Commerce, Magento, Sitefinity, and many others. The CEO of Bridgeline Digital, Ari Kahn, says, "We are excited to be the first ISV with a 3rd party connector that provides AI-powered search and recommendations for Optimizely B2C customers."

08:46 EDT Primoris anounces solar project award with an estimated value of $130M - Primoris Services announced a solar project award with an estimated value of $130M. The contract was secured by the Company's Energy/Renewables Segment. "This is a significant contract, not just by its size, but for what it says about the strength of our customer relationships," said Tom McCormick, President and Chief Executive Officer of Primoris. "Being chosen by clients on a repeat basis - in this case for our fourth project - is a real point of pride for our entire team in this partnership. For our renewables team especially, it demonstrates our ability to successfully execute our work." The award is for the engineering, procurement and construction of a utility-scale solar facility in the Southwest. Initial project construction will begin in the first quarter of 2022 with completion of the project expected in the fourth quarter of 2022.

08:45 EDT Orphazyme establishes at-the-market offering program with Cowen - Orphazyme announces that it has filed with the U.S. Securities and Exchange Commission a prospectus supplement relating to a U.S. At-the-Market Offering Program, pursuant to which the Company may issue and sell American Depositary Shares having an aggregate offering price of up to $50,000,000, each ADS representing one ordinary share of the Company, to be sold in the United States at market price, from time to time, at its option, in "at the market" transactions on The Nasdaq Global Select Market. The ADSs are intended to be sold pursuant to a Sales Agreement with Cowen and Company. The timing of any sales will depend on a variety of factors. The ADSs intended to be sold under the Sales Agreement, if any, will be issued and sold by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or in negotiated transactions, if authorized by the Company, in each case, pursuant to the Company's effective shelf registration statement on Form F-3. Any ADSs representing ordinary shares will be issued through capital increases without any pre-emption rights for existing shareholders subject to the Board of Directors deciding to increase the share capital in connection with each such issuance. The aggregate number of any such ADSs sold under the ATM Program is expected to be disclosed on a weekly basis or such longer period as may be agreed with Nasdaq Copenhagen. No assurance can be made that sales under the ATM Program will take place. To the extent that ADSs are issued pursuant to the ATM Program, the Company expects to use the net proceeds from sales of any ADSs pursuant to the ATM Program to continue the regulatory approval process for and fund the commercial launch, if approved, of arimoclomol for the treatment of Niemann-Pick disease type C and for working capital and general corporate purposes.

08:43 EDT Telos awarded additional $3.1M contract with NGA - Telos announced a $3.1M, five-year contract with the National Geospatial-Intelligence Agency, NGA. "Given NGA's mission to deliver world-class geospatial intelligence to support national security, efficient and precise identification and remediation of issues is a topline priority," said John B. Wood, CEO and chairman, Telos. "We're honored to build on our long history with the agency to ensure NGA can effectively manage cyber risk and streamline security compliance."

08:41 EDT Processa Pharmaceuticals reports results of capecitabine in Phase 1b analysis - Processa Pharmaceuticals announced that the Company's Next Generation Capecitabine dosage regimen successfully inhibited dihydropyrimidine dehydrogenase, altering the metabolism of 5-fluoruracil at least during the first 24-48 hours after PCS6422 administration but not throughout the 7 days of capecitabine dosing. If Next Generation Capecitabine inhibits the metabolism of 5-FU throughout capecitabine dosing, the combination product could be a more potent and safer cancer treatment than current chemotherapy drugs including FDA approved capecitabine, opening a multi-billion-dollar cancer chemotherapy market across multiple types of cancer. From the pharmacokinetic analyses of capecitabine, 5-FU, and their metabolites on days 1 and 7 of capecitabine treatment, the one-day dosing of PCS6422 irreversibly inhibited dihydropyrimidine dehydrogenase on day 1 of capecitabine dosing in the first 2 Cohorts of the Phase 1b trial resulting in: less than 10% of 5-FU being metabolized to FBAL compared to 80% reported with FDA approved capecitabine, a significantly longer half-life of 5-FU (i.e., 3-4 hours) than reported for FDA approved capecitabine, and 5-FU potency based on exposure per mg of capecitabine administered being at least 50 x 5-FU potency based on the exposure reported for current FDA approved capecitabine. There was little DPD inhibition found seven days after PCS6422 dosing allowing the 5-FU from the Next Generation Capecitabine to be metabolized to FBAL, similar to current FDA approved capecitabine.

08:40 EDT Save Foods expands research collaboration with University of California - Save Foods announced that following the completion of several successful field trials of Save Foods' pre-harvest products conducted by Dr. Jim Adaskaveg, Professor at the Microbiology and Plant Pathology Department at the University of California, Riverside, the Board of Directors of the Company approved increased collaboration with this university and instructed the Company's scientific team to present a working plan for the pre-harvest application within the coming 90 days. The previous studies demonstrated that pre-harvest applications of Save Foods' products are effective at mitigating the presence of decay-causing pathogens on the surface of citrus fruits. Removing pathogen inoculum loads reduces the main decays of citrus such as Penicillium, sour rot, Alternaria rot, Mucor rot, and Rhizopus rot. To ensure the harvest of higher quality fruits and to avoid/reduce food waste, treatment against the pathogens starts in the field. Currently, the number of treatment applications is strictly monitored and limited. In a press release issued on October 20 of this year, the Company reported that for the last couple of years, its products were tested to evaluate the efficacy and impact of pre-harvest treatments on the quality of citrus fruit varieties. These studies, conducted by Dr. Adaskaveg, suggested that the shelf life of citrus fruits can be significantly improved when treated with Save Foods' products prior to harvest.

08:39 EDT Soligenix's RiVax vaccine shows ricin poisoning protection in publication - Soligenix announced publication of pre-clinical immunogenicity studies for RiVax ricin toxin vaccine demonstrating enduring protection for at least 12 months post-vaccination. These results are said to reinforce the practicality of stockpiling and potentially utilizing the RiVax vaccine in warfighters and civilian first responders without the complexities that arise for vaccines that require stringent cold chain handling. This same thermostabilization approach is also being advanced in the development of Soligenix's CiVax vaccine for COVID-19. RiVax is the Company's vaccine candidate for the prevention of death following exposure to a lethal dose of ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. Approval for RiVax will be pursued under the FDA "Animal Rule," which is applied to products where testing in clinical efficacy trials would be unethical. Non-dilutive funding for the development of RiVax(R) has exceeded $40M to date. RiVax has received Orphan Drug and Fast Track designations from the FDA and Orphan Drug designation from the European Medicines Agency.

08:38 EDT Eyenovia announces first patient enrolled in Phase 3 VISION-2 trial - Eyenovia announced that the first patient has been enrolled in the Company's second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in near vision, known as VISION-2. "Following the completion of VISION-1 study, we are pleased to initiate this second Phase 3 trial that, if successful, will contribute to the clinical evidence supporting a new drug/device combination application to the US FDA," stated Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. "By leveraging the numerous benefits of our microdose array print technology, we believe MicroLine has the potential to be among the first drug treatments to improve blurred near vision that can adversely impact quality of life in patients with presbyopia." The VISION-2 study is a double-masked, placebo-controlled, cross-over superiority trial in which approximately 140 subjects with presbyopia will be treated. During the study, subjects will be randomly assigned to a treatment sequence for dosing with pilocarpine 2% as well as placebo, both administered via the Optejet dispenser. The primary endpoint is improvement in high contrast binocular distance corrected near visual acuity measured in low light conditions 2 hours after treatment. Topline data is expected in mid-2022.

08:37 EDT Digital Brands confirms acceptance of cryptocurrencies as form of payment - Digital Brands Group (DBGI) announces it will start accepting cryptocurrencies as a form of payment across all its brands. "Shopify (SHOP) enables our brands to accept cryptocurrencies as a form of payment. We believe this form of payment will continue to grow as a potential currency in our industry," stated Hil Davis, CEO of Digital Brands Group. "Finally, as we discussed in our S-1, we expect to continue to grow through acquisitions and expect to continue to acquire companies this year, most of which will require GAAP PCAOB audits. These audits take time, which results in a delayed acquisition timeframe weighted toward the final months of 2021."

08:36 EDT Enlivex granted authorization from Spanish AEMPS to expand Sepsis Phase II - Enlivex Therapeutics announced that the Spanish Agency of Medicines and Medical Devices, AEMPS, has authorized the expansion to clinical sites in Spain of the Company's multi-center, placebo-controlled, randomized, dose-finding, Phase II trial of AllocetraTM in patients with pneumonia-associated sepsis. The Phase II trial, which has multiple sites open for enrollment in Israel, is expected to include 120 to 160 patients across four cohorts receiving varying doses of AllocetraTM or placebo, all in addition to standard-of-care therapy. The trial's two primary endpoints are safety and efficacy assessments throughout a 28-day follow-up period. Oren Hershkovitz, Ph.D., CEO of Enlivex, commented, "Receiving authorization to expand our sepsis trial to Spain is an important first step in our broader plan to include several European countries as part of our ongoing clinical trials. We believe this also represents a notable regulatory achievement that provides additional validation for our study design and Allocetra's manufacturing process, which was reviewed by the Spanish regulator as part of its review process. We would like to thank AEMPS for their review and look forward to the continued advancement of our sepsis program across both Europe and Israel."

08:35 EDT Ballard Power announces orders for 40 fuel cell modules in European market - Ballard Power announced orders for a total of 40 FCmoveTM-HD modules for planned deployment in hydrogen fuel cell electric buses across Europe in 2022. These FCEBs are being deployed in France, Germany, and the UK.

08:34 EDT Oyster Point Pharma announces patient support program for TYRVAYA - Oyster Point Pharma announced it has launched a patient support program called TEAMTyrvaya where eligible patients can pay as little as $0 for TYRVAYA Nasal Spray 0.03 mg. The U.S. Food and Drug Administration approved TYRVAYA Nasal Spray for the treatment of the signs and symptoms of dry eye disease on October 15, 2021. TYRVAYA Nasal Spray is a highly selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production. John Snisarenko, Chief Commercial Officer of Oyster Point Pharma stated, "Oyster Point Pharma is committed to helping people with dry eye disease have access to the treatments they need and therefore have established comprehensive patient affordability and access programs, including a co-pay savings offer to allow eligible patients with commercial insurance to pay as little as $0 for TYRVAYA Nasal Spray." Mr. Snisarenko added, "We are working closely with the eye care provider community to share these resources with their constituents and help people with dry eye disease have access to the resources they need."

08:33 EDT Sema4 Holdings, Mount Sinai use machine learning to improve PPH risk - Sema4 recently published two studies demonstrating the utility of machine learning to predict clinical outcomes for postpartum hemorrhage, PPH. The studies, which will appear in a special "Informatics for Sex- and Gender-Related Health" print issue of the Journal of the American Medical Informatics Association, were conducted in collaboration with clinicians from the Mount Sinai Health System. "These two new papers are among the first to use large-scale, comprehensive real-world data to predict clinical outcomes," said Eric Schadt, PhD, Founder and Chief Executive Officer of Sema4 and joint corresponding author on the papers. "By implementing our predictive model into the clinical standard of care, healthcare providers may be able to improve PPH risk assessment and medical management for their pregnant patients resulting in better health outcomes." The first study leveraged de-identified longitudinal electronic medical record data on over 70,000 pregnancy deliveries at five Mount Sinai Health System hospitals to develop and validate a comprehensive digital phenotyping algorithm for PPH. The novel algorithm incorporates not only cumulative blood loss but also other critical diagnostic and treatment-related features indicative of PPH. The same patient cohort was used in the second study to build, train, and validate a predictive model for PPH risk using advanced machine learning methods. The model uses 24 predictive markers, including five new potential PPH risk factors. In comparison tests, Sema4's novel tool outperformed three existing clinical risk-assessment tools and models.

08:32 EDT Clear Secure expands to terminal B t Boston Logan International Airport - Clear announced its trusted and secure identity technology and expedited lanes are now available at Boston Logan International Airport's Terminal B. With this expansion, Clear's expedited security lanes are now available at Terminals A and B. This announcement will mean the creation of 20 new jobs and an overall economic impact of upwards of $3.3M for the Boston Logan International Airport and Boston from the addition of two Clear lanes.

08:32 EDT Enphase Energy, NexGen Construction expand partnership - Enphase Energy announced that NexGen Construction, a Southern California-based contracting service company that specializes in the design build of solar energy systems for residential customers, is continuing to grow its business due to the rapid expansion of battery storage systems and is using exclusively Enphase products. NexGen Construction, a new Enphase Installer Network Platinum member, has seen increased interest in home battery systems over the past several years as power shutoffs become more frequent and energy prices continue to rise. Homeowners are seeking energy systems with Enphase IQ Batteries as smart, reliable, and safe solutions to keep the lights on, while giving them greater control over their energy future.

08:31 EDT Healthcare Triangle releases methodology for blockchain transformation - Healthcare Triangle announces the release of Blockedge Glu, which provides a framework and methodology for a blockchain transformation of pharma supply chain eco system in partnership with blockedge.io a leading blockchain transformation provider. "FDA's requirements alone are not the driving factor behind accelerating the blockchain transformation of pharma supply chain", says Chairman and CEO of Healthcare Triangle, Suresh Venkatachari. "Blockchain is the best track & trace solution available for us today, giving complete end-to-end supply chain visibility, thus can make a significant difference, if adopted right." Venkatachari continued, "Blockedge Glu is designed to make this adoption right by addressing major challenges involved by providing a framework which reduces the complexities of integrating existing large and complex IT systems with one or more blockchain networks while also providing a transformation methodology that servers as a playbook for IT and business leaders to implement, what's becoming to be, the multi-year transformation program."

08:29 EDT Harsco's Clean Earth launches Orbit, new point-of-sale software - Clean Earth, a division of Harsco Corporation and a leading provider in environmental and regulated waste management services, announced the launch of its Orbit Service Software, a new, proprietary internal point-of-sale, POS, system developed by Clean Earth that will help Clean Earth drivers better service customers across a variety of industries. Today's launch is the first phase of the Orbit service software rollout and will include several customer service enhancements over the previous system. "We're raising the bar on customer experience with the launch of Clean Earth's Orbit service software," said David Stanton, Clean Earth President. "We built this software to fulfill our sincere desire to provide high-quality service, every time. As we have engaged our customers, they have made it clear that quality of service, as well as regulatory compliance, is a significant factor in selecting their service provider. By supplying real- time data to our customers, this software improves efficiencies, creates a higher-quality of service and helps to minimize our customers' carbon footprint as well as our own." Clean Earth has begun rolling out the Orbit service software to its retail customers and hopes to make it available to the rest of the Clean Earth customer base in 2022.

08:29 EDT Brigham Minerals acquires interests in DJ Basin for $44M - Brigham Minerals has entered into a definitive purchase and sale agreement to acquire certain mineral and royalty interests in the DJ Basin for approximately $44M in cash and approximately 2.2 million shares of Class A common stock subject to certain closing adjustments. Characteristics include: 8,400 net royalty acres primarily in Weld County operated by PDC Energy, Chevron, Occidental Petroleum and Civitas Resources. 2022 estimated production totaling between 1,100 to 1,200 boepd and 50% liquids. 2022 estimated high teens EBITDA yield. Anticipates increasing quarterly base dividend 7% to 15c per share post-close. Pro forma net activity wells of 13.3 as of September 30. Brigham intends to finance the $44M cash portion of the purchase price through a combination of cash on hand and borrowings under the Company's revolving credit facility. Borrowing base is expected to increase to $230M upon closing of the DJ Acquisition. Post-close pro forma liquidity of nearly $150M and less than 0.7X net debt / Adj. LTM EBITDA. August 1st effective date with anticipated close in mid to late December subject to continued diligence and closing conditions.

08:28 EDT Bionano Genomics appoints Hoyle, Helm as VPs - Bionano Genomics (BNGO) announced that two former Illumina (ILMN) executives, Stephanie Hoyle and Alex Helm, have joined the company as vice presidents, VP, of Corporate Marketing and Strategic Product Marketing, respectively. At Bionano, Stephanie will oversee global marketing and brand strategy for the Company. Alex will be responsible for developing the long-term, global product roadmap and portfolio strategy for Bionano's set of products and service solutions to influence the Company's annual strategic planning process.

08:27 EDT VYNE Therapeutics announces preclinical data at VYN201 - VYNE Therapeutics announced preclinical data from a validated animal study showing that its bromodomain and extra-terminal inhibitor, VYN201, demonstrated improvements in reducing fibrotic tissue mass and overall skin repair outcomes with no negative impact on healing time. VYNE is evaluating its lead BET inhibitor, VYN201, for several autoimmune skin diseases that are characterized by lesions, such as chronic ulcers and blisters, which are challenging to treat and can potentially lead to severe infections and surgical intervention. Frequently used treatments for neutrophilic dermatoses are known to significantly delay the healing of lesions1 and, in this context, VYNE conducted a validated preclinical study to evaluate the effect of VYN201 on skin healing and repair. In the preclinical study, duplicate identical skin incisions were induced on the flanks of hairless mice under anesthesia. The animals were topically dosed once daily with either 100mg VYN201 vehicle, VYN201 1%, or a hydroalcoholic gel until each lesion had completely healed. Key findings from the study: As early as treatment day 5, and consistent with the vehicle control, animals treated with VYN201 1% had a statistically significant decrease in global external lesion severity score, a comprehensive evaluation of length, width, swelling and visibility of lesions, compared to those treated with hydroalcoholic gel. Consistent with the vehicle control, lesions treated with VYN201 1% completely healed approximately 5 days earlier compared to those treated with hydroalcoholic gel. Animals treated with VYN201 1% had a significantly lower global internal lesion severity score that hose treated with VYN201 vehicle or hydroalcoholic gel, indicative of an improved internal lesion outcome and a positive effect on reducing the formation of fibrotic tissue mass in the lesion bed. By the end of treatment, healed lesions treated with VYN201 1% appeared less visually distinct and more macular in nature with an improved overall aesthetic outcome compared to the other treatments. VYN201 vehicle and VYN201 1% appeared to be well-tolerated both within the lesion sites, based on the absence of irritation, and in general throughout the treatment period.

08:26 EDT Ready Capital announces merger transaction - Ready Capital has entered into a definitive merger agreement to acquire a series of privately held, real estate structured finance opportunities funds, with a focus on construction lending, managed by MREC Management. Following the mergers, Ready Capital is expected to have a pro forma equity capital base in excess of $1.7B. Ready Capital will acquire all of the outstanding equity interests in Mosaic Real Estate Credit, Mosaic Real Estate Credit TE, and MREC International Incentive Split, the "Mosaic Merger Entities" in exchange for shares of a newly designated Ready Capital Class B common stock plus non-transferable contingent equity rights that may entitle investors in the Mosaic Funds to receive additional shares of Ready Capital common stock. The newly issued Class B Common Stock will not be listed on the NYSE. As of June 30, investors in the Mosaic Funds would receive approximately 30.3 million shares of Class B Common Stock. The implied value of the Ready Capital shares expected to be issued in connection with the closing is approximately $471M and the maximum possible payment under the CERs would be an additional approximately $89M of Ready Capital common stock. Holders of CERs will have the right to receive dividends. Upon closing, Ready Capital stockholders are expected to own approximately 70% of the combined company's stock, while holders of interests in the Mosaic Funds are expected to own approximately 30% of the combined company's stock. Market capitalization of the combined company would be approximately $1.6B. The combined company will continue to operate under the name Ready Capital and its shares are expected to continue trading on the NYSE under the existing ticker symbol "RC" and Waterfall Asset Management will continue to manage the combined company. Mosaic Manager will be led by Ethan Penner. The transaction is expected to close during 1Q22.

08:24 EDT SynBio Innovation Accelerator enables $10M investment in Molecular Assemblies - Codexis and Casdin Capital announced a combined $10 million investment enabled by their SynBio Innovation Accelerator in the Series B funding round of Molecular Assemblies, a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. Codexis and MAI are established partners in a collaboration to develop differentiated and cost-effective solutions to commercialize the enzymatic synthesis of DNA. Since the partnership's inception in June of 2020, Codexis has been applying its CodeEvolver platform technology to improve the DNA polymerase enzymes that are critical for enzymatic DNA synthesis; Molecular Assemblies has been combining its advanced chemistries with Codexis' enzymes to drive the process to commercialization. Codexis has a seat on the MAI board of directors and is now the company's second largest shareholder.

08:23 EDT Talaris Therapeutics provides update on Phase 3 FREEDOM-1 study - Talaris Therapeutics provided the first clinical update on its Phase 3 FREEDOM-1 study in living donor kidney transplant recipients, and also separately presented a clinical update and additional data from ongoing follow-up of its fully-enrolled Phase 2 study in LDKT recipients at the 2021 American Society of Nephrology meeting. In the Phase 3 FREEDOM-1 study, the first two study patients whose LDKT occurred more than 12 months prior to the data cutoff date were both successfully weaned off all chronic immunosuppression drugs without evidence of rejection and with stable kidney function and continue to remain off all IS through the data cut-off date. Furthermore, all patients treated at least three months prior to the cutoff date with the company's Facilitated Allo-HSCT Therapy, FCR001, achieved T-cell chimerism levels greater than50% at each of the 3-, 6-, and 12-month timepoints post-transplant. In the company's Phase 2 study, establishment and maintenance of greater than50% donor peripheral T-cell chimerism in an LDKT recipient at 3, 6 and 12 months after administration of FCR001 all correlated strongly with the patient's ability to durably discontinue chronic IS approximately one year after transplant, without subsequent graft rejection. The company also presented "Preserved kidney allograft function and unique urinary biomarker profiles in living-donor kidney transplant patients tolerized with an investigational allo-HSCT cell therapy" at the 2021 ASN meeting. This poster reported that, in continued long-term follow-up of patients treated in the company's Phase 2 study of FCR001 (median greater than6 years), kidney allograft function was preserved in all patients who had been successfully weaned off chronic IS and such patients have continued to remain off chronic IS for the duration of their follow up. Further, Talaris reported that it has identified potential signals of immune quiescence in the kidneys of some of its Phase 2 LDKT patients who were tolerized to their donated kidney, as compared to standard of care kidney transplant patients.

08:22 EDT SAIC wins $93M U.S. Navy contract to provide networks, infrastructure support - Science Applications International won a contract to compete for task orders worth up to $93M supporting Tactical Integrated Threat/Target Training Systems for the U.S. Navy's Adaptive Combat Environment Systems group at Naval Air Station, China Lake, California. Under the five-year, indefinite-delivery/indefinite-quantity contract, SAIC will compete with other selected vendors to provide research and development, engineering, integration, testing, cybersecurity, upgrades and sustainment for numerous tactical threat systems to help improve Navy aircrew effectiveness and survivability. The Navy expects to complete work on this cost-plus-fixed-fee, firm-fixed-price contract in September 2026. "This award gives SAIC an opportunity to win specific task orders under the TTS contract to help verify and validate the system capabilities deployed to our Navy," said Josh Jackson, senior vice president of the Naval Business Unit, SAIC. "This will ultimately help us better serve and support the Navy's current and future range capabilities."

08:21 EDT Vera Bradley collaborates with Peanuts for Snoopy-themed holiday collection - Vera Bradley announced its first-ever collaboration with beloved brand Peanuts on a new Snoopy-themed holiday collection. The Vera Bradley + Peanuts collection features three limited-edition patterns - "Ski Slope Snoopy," "Snoopy Fair Isle" and "Ski Jump Snoopy" - and is available now in all Vera Bradley Full Line Stores, in select Vera Bradley Factory locations and online at verabradley.com. The Vera Bradley + Peanuts collection, offered in the brand's newest Recycled Cotton fabrication, features Snoopy and his pal Woodstock enjoying wintry weather at a colorful vintage ski resort. Hand-drawn elements and plenty of paisleys in a palette of jewel tones complete the pattern with signature Vera Bradley style. The Vera Bradley + Peanuts collection is available in best-selling silhouettes like the Plush Throw Blanket, Vera Tote and Large Duffel, alongside brand-new styles created exclusively for the collaboration - including a line of cozy sleepwear for the entire family. The collection's 71 total styles range in price from $14.95 to $150

08:20 EDT OncoCyte announces clinical launch of DetermaIO test - Oncocyte announced the clinical launch of its DetermaIO test. DetermaIO is a proprietary gene expression test that assesses the tumor immune microenvironment, TIME, to predict response to immunotherapy. In multiple clinical studies evaluating hundreds of patients across multiple tumor types, including lung, breast, bladder and renal cancers, the test has demonstrated the ability to predict response to immune checkpoint inhibitors which has the potential to help inform the optimal use of immunotherapy treatment for more than one million eligible patients annually in the United States alone. Padma Sundar, Chief Commercial Officer of Oncocyte, said, "Given the data presented to date, there is strong interest among physicians to access this test and incorporate it into their practice to aid in the complex decision making for immunotherapy treatment. We are launching the test initially as part of an early access program to optimize sample processing and logistics, targeting sites that have successfully partnered with Oncocyte on prior tests. Recruitment for the early access program is ahead of schedule and clinical samples are expected to begin coming in before the end of the year. Demonstrating test adoption is an important step towards pursuing Medicare reimbursement, along with peer reviewed publications which are in process, and we remain committed to deliver our reimbursement dossier in the first half of 2022." The launch of DetermaIO is built on the growing body of evidence on the clinical applications of the test, suggesting a potential pan-cancer and pan-immunotherapy utility in both primary and metastatic settings.

08:18 EDT Orion Energy appoints Michael Jenkins as COO - Orion Energy Systems announced the expansion of its executive management team with the appointment of Michael Jenkins as COO to support the Company's long-term growth objectives. Mr. Jenkin will assume Orion's COO role from Scott Green. Mr. Green is being promoted to President of Orion Services Group, which encompasses the Company's turnkey lighting installation and maintenance services business. Mr. Jenkins has over 25 years of operations, sales and marketing experience, including the past eight years as the Construction and Consumer Business Director & General Manager at Bostik.

08:17 EDT Draganfly to present the Drone Racing League's 'Why I Fly' series - Draganfly announced that it will present the Drone Racing League's "Why I Fly" Series as part of their multi-year partnership with DRL, the world's premier, professional drone racing property. "Why I Fly" is a series of short videos spotlighting the personal journeys of elite DRL pilots into the world of drone flying. The series will be released during the 2021-22 DRL World Championship Season which airs on Wednesday nights at 8pm EST on NBCSN and Twitter. DRL has already released several features on individual pilots, which cover topics including their training regiments and thoughts on how to deal with competition during races. More information on DRL's pilots can be found here.

08:15 EDT Ardelyx to pursue formal dispute resolution for tenapanor - Ardelyx announced the company plans to submit a Formal Dispute Resolution Request to appeal the issuance of a Complete Response Letter from the U.S. Food and Drug Administration for the company's New Drug Application for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease on dialysis. Formal Dispute Resolution is a pathway in the Center for Drug Evaluation and Research by which NDA applicants can seek to resolve scientific and/or medical disputes that cannot be resolved at the division level. "While we are disappointed that we could not come to a resolution with the Division of Cardiology and Nephrology during the End of Review meeting, the Formal Dispute Resolution process provides an opportunity to raise our scientific disagreement above the division level within CDER," said Mike Raab, president and CEO of Ardelyx. "We believe that this represents the best approach to obtaining approval of tenapanor for the treatment of hyperphosphatemia and bringing this important medicine forward to patients and their treating physicians."

08:12 EDT NeuroBo Pharmaceuticals names Gil Price, M.D. as CEO - NeuroBo Pharmaceuticals announced that the company has appointed Gil Price, M.D. as President and CEO. Dr. Price will replace Dr. Richard Kang, Ph.D., who is stepping down later this month to pursue other opportunities, while remaining on the Board of Directors. In the interim, Dr. Price will serve as the Chief Medical Officer of the Company. Dr. Kang has also agreed to continue to serve on the NeuroBo Board of Directors and consult for NeuroBo for a period of up to one year in order to help ensure an orderly transition.

08:11 EDT Cboe Global Markets to launch new U.S. Treasuries trading platform - Cboe Global Markets announced plans to introduce a new dealer-to-dealer electronic trading platform for On-The-Run U.S. Treasuries. The platform will be Cboe's first cash U.S. Fixed Income product offering, further diversifying and expanding its products, services and technology offerings into new markets and geographies around the world. Cboe Fixed Income is planned for launch in the second quarter of 2022, subject to regulatory approvals. The new trading platform is designed to better enable dealers in U.S. Treasuries to efficiently source liquidity and trade in size, while reducing market impact. This new platform will leverage the expertise and proven track record of Cboe FX, a global leader in electronic trading for 20 years with a reputation for world-class technology, cutting-edge liquidity solutions, product innovation and trading reliability and efficiency.

08:10 EDT Cheniere Energy Partners sees FY22 distribution per unit $3.00- $3.25 -

08:09 EDT Marathon Gold provides commentary on EA process in Newfoundland, Labrador - Marathon Gold Corporation is providing additional information on the status of the Newfoundland and Labrador Environmental Assessment process for the Valentine Gold Project. The Valentine Gold Project is subject to regulation under the environmental protection regimes of the Canadian Environmental Assessment Act, 2012 and the NL Environmental Protection Act. Marathon filed a project description with both the Impact Assessment Agency of Canada and the NL Department of Environment and Climate Change on April 5, 2019, which was accepted into the formal EA process on April 16, 2019. An NL Environmental Assessment Committee for the Project was established on July 3, 2019, and the Project's Environmental Impact Statement was filed on September 29, 2020. The EIS was accepted as conforming with guidelines on November 3, 2020, allowing its formal review to begin. The federal and provincial EA processes provide for the technical review of the EIS by multiple government agencies and the opportunity for public comment. Following regulatory and public review, federal Information Requirements and provincial review comments were issued to Marathon in February 2021. The IRs and review comments are a routine part of the EA process, reflecting requested clarifications or information on various aspects of the EIS received from regulators, Indigenous groups, the public, and other stakeholders. Marathon completed the submission of responses to 76 federal IRs on May 3, 2021. Responses to 362 provincial review comments were submitted on August 3, 2021, which in the case of the provincial process takes the form of an amendment to the EIS. IAAC subsequently issued a second round of 23 IRs, to which Marathon submitted responses on October 18, 2021. On October 29, 2021, Marathon was informed by the NL Minister of Environment and Climate Change that the EAC had completed its review of the amended EIS and that a second round of review comments were being issued by the province, with responses to take the form of a further amendment to the EIS. In his letter of October 29, 2021, the Minister cited ten categories of deficiency on the current, amended EIS for which the further review comments were being issued. These are: Caribou Protection and Effects Monitoring; Victoria Lake Reservoir and Victoria Dam Effects and Mitigations; Effects on Human Health; Green House Gas Emissions; Baseline Survey of Fish Populations in Victoria Lake and Valentine Lake; Acid Rock Drainage, Metal Leaching and Potentially Acid Generating Materials; Consultation with Outfitters; Surface Water and Groundwater Modelling and Monitoring; Tailings Management; and, Cumulative Affects Assessment. Marathon has completed a preliminary assessment of the requests behind each of these stated categories. They include the recharacterization of existing data or data models for different operating circumstances; additional modelling of specific water management scenarios under alternate climate or bedrock conditions; the resubmission of existing data in alternative formats; the provision of new environmental baseline data that Marathon has collected since the submission of the first EIS amendment; direction on future environmental monitoring to be required during the Project's development and operation; and, the completion of certain management plans, including plans being actively developed by Marathon in collaboration with divisions of the NL Government. Management plans referenced in the Minister's communications include the following: a NL Benefits Agreement, containing a Human Resources Plan and a Gender Equity, Diversity and Inclusion Plan, now substantially completed and awaiting final approval by the NL Government; an Outfitters Environmental Effects Monitoring Plan, currently being developed in collaboration with the NL Outfitters Association pursuant to an October 4, 2021 Memorandum of Understanding between Marathon and the NLOA; and, a Caribou Protection and Environmental Effects Monitoring Plan, which is being developed in coordination with the Wildlife Division of the NL Department of Fisheries, Forestry and Agriculture. The Caribou Plan is being designed to address potential risks posed to caribou by the Project. Such risks are primarily to the seasonal migratory patterns of the Buchans herd, one of several on the island of Newfoundland and representing approximately 13% of the island's caribou population. The Caribou Plan contains continuous monitoring strategies to assess potential impacts to caribou during the life of the Project. It will define specific behavioural thresholds designed to trigger mitigation options in an adaptive management structure, and will benefit from several years of existing caribou data collected by either the Wildlife Division of the NL DFFA or Marathon, such as GPS collaring, trail cameras, population surveys and other supporting studies. The Caribou Plan will also include the cessation of mining activities in the Marathon open pit and associated haul road during the short fall and spring caribou transit periods, a provision already accounted for in the Project's mine planning, and it will include Marathon's commitment of financial support for ongoing regulatory review and assessment of caribou monitoring data. Marathon considers the Caribou Plan to be well advanced.

08:08 EDT Lipocine: FDA grants Fast Track Designation to LPCN 1144 - Lipocine announced that the U.S. FDA has granted Fast Track Designation to LPCN 1144 as a treatment for non-cirrhotic non-alcoholic steatohepatitis. LPCN 1144, an oral prodrug of bioidentical testosterone, was recently studied in the Liver Fat intervention with oral Testosterone Phase 2 paired biopsy clinical study in patients with confirmed NASH. Treatments with LPCN 1144 in the LiFT clinical study resulted in robust liver fat reduction, assessed by magnetic resonance imaging, proton density fat fraction technique, and showed improvement of liver injury markers with no observed tolerability issues. Additionally, key secondary endpoint results after 36 weeks of treatment in the LiFT clinical study demonstrated that treatments with LPCN 1144 met the NASH resolution regulatory endpoint, showed positive effects in appendicular lean mass and whole-body fat mass and continued to show substantial reductions in markers of liver injury compared to placebo.

08:06 EDT OpGen appoints Albert Weber as CFO - OpGen announced the appointment of Albert Weber as OpGen's new Chief Financial Officer and Managing Director of OpGen's subsidiary Curetis GmbH effective January 1, 2022. Mr. Weber is a corporate finance executive who brings more than 30 years of professional experience in accounting, controlling and corporate finance roles. During the last 21 years, he served in several roles for Epigenomics AG, a molecular diagnostics company listed on the Frankfurt Stock Exchange, with operations in the United States and Germany. Since 2018, Mr. Weber served as Executive Officer and Executive Board member and EVP Finance. Mr. Weber will initially be based in Germany and work primarily out of the Company's Curetis GmbH office in Holzgerlingen near Stuttgart, but expects to spend a significant amount of time at the U.S. headquarters in 2022 and beyond as he will oversee and manage the global finance teams in their entirety. Inducement Grant under NASDAQ Listing Rule 5635(c)(4) In connection with the appointment of Mr. Weber, OpGen granted Mr. Weber an inducement grant of stock options to purchase an aggregate of 210,00 shares of OpGen's common stock with a grant date of January 3, 2022. The equity award was granted pursuant to Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a component of Mr. Weber's employment compensation and was granted as an inducement material to his acceptance of employment with OpGen. The options will have an exercise price equal to the closing price of OpGen's common stock as reported on Nasdaq on January 3, 2022, the first trading day after Mr. Weber's start date. The option award will vest over a four-year period with 25% vesting on the first anniversary of the date of grant and in equal quarterly installments on each quarterly anniversary thereafter. The award is subject to Mr. Weber's continued service with OpGen through the applicable vesting dates.

08:04 EDT Beyond Air announces separation of oncology business - Beyond Air announced the separation of its oncology business into a new and independently managed, private company called Beyond Cancer, Ltd. Beyond Air retains its respiratory business and will continue to focus on advancing the LungFit platform of nitric oxide generators and delivery systems to the market. Beyond Air's preclinical oncology team and the exclusive right to the intellectual property portfolio utilizing UNO for the treatment of solid tumors now reside with Beyond Cancer. Beyond Air believes the spin-off of the oncology business will create long-term value for shareholders through the following: Beyond Air's focus remains advancing the LungFit platform to treat respiratory diseases, and the oncology program does not use LungFit given the ultra-high concentrations and direct delivery to the site of the tumor; After this financing, Beyond Air will retain at least 80% equity ownership in Beyond Cancer; Beyond Cancer will pay Beyond Air a single digit royalty on all future revenues; Beyond Cancer will benefit from Beyond Air's NO expertise, IP portfolio, preclinical oncology team, and regulatory progress; Beyond Cancer can initially utilize Beyond Air's infrastructure while having its own investor base and dedicated leadership team with clinical oncology experience to accelerate and enhance its solid tumor pipeline Selena Chaisson, M.D., is joining Beyond Cancer as Chief Executive Officer. Previously, Dr. Chaisson was the Director of Healthcare Investments at Bailard, where she spent 16 years focusing on highly specialized, emerging healthcare opportunities with more than one-third of her portfolio dedicated to investments in oncology-related companies. Beyond Cancer has secured commitments of $23.9 million in a concurrent private placement of common shares, not to exceed $30 million, providing the investors with up to 20% equity ownership. The funding is expected to be used to accelerate ongoing preclinical work including the completion of IND-enabling studies, completion of a Phase 1 study, expansion of preclinical programs for combination studies, hiring of additional Beyond Cancer team members, and optimization of the delivery system, as well as for general corporate purposes. The concurrent private placement is expected to close later in the fourth fiscal quarter.

08:02 EDT NFI Group's New Flyer of America selected by CapMetro for EV, charger contract - NFI Group announced that the Capital Metro Transportation Authority, CapMetro, has awarded NFI subsidiary New Flyer of America a contract for 26 battery-electric Xcelsior CHARGE NG forty-foot heavy-duty transit buses and four battery-electric Xcelsior CHARGE NG sixty-foot heavy-duty transit buses. The five-year contract includes options to purchase up to 126 forty-foot and up to 15 sixty-foot battery-electric buses, and up to 427 chargers. New Flyer's Xcelsior CHARGE NG battery-electric buses deliver up to 525kWh of power and 250 miles of range on a single charge and, over a 12-year lifespan, offer up to $125,000 in maintenance savings and up to $400,000 in fuel savings.

08:02 EDT Dun & Bradstreet to acquire Eyeota and NetWise, no terms - "Dun & Bradstreet Holdings announced that it has entered into definitive agreements to acquire Eyeota and NetWise. These acquisitions will extend the Company's position in the B2B online marketing value chain and will build upon its rapidly growing Audience Solutions business by adding global scale and the online data to power omni-channel marketing around the world," the company said in a release. "Dun & Bradstreet's acquisitions of Eyeota and NetWise will cap-off several years of investment in the Sales and Marketing space, including the acquisition of our Customer Data Platform, Lattice Engines, which is at the core of our D&B Rev.Up platform, and the acquisition of Orb Intelligence to link digital and physical businesses in our Data Cloud," said Stacy Greiner, General Manager of the Sales & Marketing business for Dun & Bradstreet. "We are executing on our vision to help revenue-generating teams get out of the business of wrangling data and technology, and back to engaging with their customers and prospects to drive growth for their companies." The Eyeota transaction is in the process of closing, and the NetWise transaction is expected to close in the next month, subject to customary closing conditions. Financial details of the transactions will be disclosed subsequently.

07:58 EDT TransMedics reports 'positive' top line results from OCS DCD heart trial - TransMedics Group announced "positive" topline results from its OCS donors after circulatory death Heart Trial. The OCS DCD Heart Trial was designed as the first and only randomized trial to compare post-transplant clinical outcomes between hearts transplanted from DCD donors that were resuscitated and assessed on OCS Heart System and hearts transplanted from donors after brain death that were preserved using the current standard of cold storage in the U.S. The primary goal was to assess the effectiveness and safety of OCS Heart technology to expand the heart donor pool to include DCD donors. The trial achieved its primary clinical objectives by meeting the primary effectiveness endpoint of 6 months patient survival post-transplant which was 95% for OCS DCD arm vs. 89% for DBD Control arm. Of 101 DCD donor hearts, 90 were successfully transplanted resulting in a utilization rate of 89%. The OCS Heart System was approved by the FDA for its DBD heart indication in September 2021. These OCS DCD Heart trial results will be submitted shortly to FDA in a PMA supplement to support the approval for the OCS DCD heart indication.

07:58 EDT DCP Midstream announces public offering of $400M senior notes - DCP Midstream announced that its wholly owned subsidiary, DCP Midstream Operating, has commenced a public offering of $400 million aggregate principal amount of its senior notes due 2032. The Senior Notes will be fully and unconditionally guaranteed by the Partnership. The Operating Partnership intends to use the net proceeds from the offering to repay indebtedness under its revolving credit facility and for general partnership purposes.

07:57 EDT BurgerFi completes $156.6M acquisition of Anthony's Coal Fired Pizza & Wings - BurgerFi International announces the completion of its pending acquisition of Anthony's Coal Fired Pizza & Wings from L Catterton for $156.6M. Ophir Sternberg, Executive Chairman of BurgerFi commented, "This acquisition marks a significant step forward in BurgerFi's ongoing growth strategy and transition into a premium multibrand platform." Anthony's is an operator of casual dining pizza restaurants with a very loyal fan base and, like BurgerFi, a high concentration of restaurants in the state of Florida. "We are very excited to officially welcome Anthony's into the BurgerFi family," continued Ophir Sternberg. "Anthony's is our first acquisition in our long term inorganic growth strategy to build a premium multibrand platform. It represents a fantastic complement to the BurgerFi brand, and we are well positioned to strategically grow Anthony's as it fits in our focus on high quality fast-casual dining restaurants. L Catterton was an excellent partner in finalizing this transaction, and we look forward to the strategic benefits of adding Andrew Taub, Managing Partner at L Catterton to our board."

07:55 EDT Houghton Mifflin narrows 2021 annualized recurring revenue view to 12%-15% - Had previously seen 2021 annualized recurring revenue view of 10%-15%.

07:55 EDT CareDx announces UAB integrated TxAccess to reach over 500 centers - CareDx announced that the University of Alabama at Birmingham, UAB, Comprehensive Transplant Institute is integrated with TxAccess to now reach over 500 dialysis centers and nephrology practices. TxAccess, a cloud-based service from CareDx, helps support more patients onto the transplant waitlist. To date, over 38,000 referrals have been managed with TxAccess as a growing number of transplant centers adopt the service.

07:54 EDT Surge Copper announces assay results from Ootsa Property - Surge Copper Corp. announced assay results for multiple resource definition holes from the Company's 100% owned Ootsa Property in British Columbia. Highlights: Hole S21-264 was targeting extensions of mineralization into the Gap Zone connecting West and East Seel. This 60-degree angled hole intersected 296 metres grading 0.53% copper equivalent from a downhole depth of 448 metres including 66 metres grading 0.75% copper equivalent Hole S21-267 was targeting the northern limits of the East Seel deposit and intersected 305 metres grading 0.46% copper equivalent from a downhole depth of 52 metres, and included 20 metres grading 1.04% copper equivalent. Drilling at the Far East Target, located 300 metres northeast of the East Seel deposit, has expanded a modest zone of near surface mineralization that remains open to the east. Assay results have been received for holes S21-262, 264, 267, and 269, with significant assay results summarized in the table below. Holes S21-262 and 264 tested the southwestern margin of the East Seel deposit and the area between the East and West Seel deposits known as the Gap Zone, and have defined a large mineralized zone at depth in that area. Hole S21-267 tested the northeast edge of the East Seel deposit and hole S21-269 expanded a modest zone of near surface mineralization 300 metres northeast of East Seel at the Far East Target. Hole S21-267 tested the northeast margin of the East Seel deposit and ended within known East Seel mineralization. The hole successfully expanded near surface mineralization on the northeast margin of East Seel, returning 0.46% copper equivalent over 305 metres including 0.57% copper equivalent over 106 metres and 1.04% copper equivalent over 20 metres. Holes S21-262 and 264 were collared on the west side of the East Seel deposit and drilled toward the southwest testing the Gap Zone. Both holes help to expand and define a zone of near surface low grade mineralization at the Gap Zone, and a larger zone of deeper mineralization that remains open at depth. Hole S21-269 was a 100 metre step out to the northeast of the Far East Target and expanded a modest zone of near surface mineralization located 100 to 300 metres northeast of the East Seel deposit. Hole S21-269 successfully expanded the Far East Target 100 metres to the northeast returning 90 metres grading 0.28% copper equivalent starting below gravel cover at 34 metres depth. The summer 2021 core drilling program at Ootsa comprised a total of 26,556 metres of drilling in 72 holes. Thus far, following this news release, results from 24 holes have been released, with results from 48 additional holes pending. Results from 45 holes focused on the shallow Breccia Zone located to the north of the Seel deposits are pending, as are holes from select regional exploration targets, and the bottom portion of hole S21-268, which is the last remaining hole to be reported from West Seel drilling. The 2021 core drilling program at the Berg deposit area has been completed for the season and will resume next summer. Nine core holes were completed at Berg for a total of 2,855 metres of drilling. All of the Berg drill core has been logged and sampled and submitted to the lab for assay. The Company anticipates updating the market on results from the following activities: Drill results from 48 remaining drill holes from 2021 Ootsa drill program; Drill results from 9 drill holes from 2021 Berg drill program; Resource update for the Ootsa project; Inversion and targeting results from regional airborne geophysics, and update on regional exploration pipeline The Company is well financed with over C$10 million in the treasury.

07:52 EDT Moderna falls 11% to $308.28 after Q3 sales miss estimates

07:51 EDT Moderna announces $1B share repurchase program over two years - Moderna said its board has authorized a share repurchase program of up to $1B over a two-year period. No shares were repurchased through the end of the third quarter.

07:50 EDT Orchard Therapeutics expects cash to fund operations into 1H of 2023 - Cash, cash equivalents and investments as of September 30, 2021, were $254.1 million compared to $191.9 million as of December 31, 2020.

07:48 EDT Enthusiast Gaming announces two conferences - Enthusiast Gaming Holdings will host two new conferences, Pocket Gamer Connects Digital NEXT and Beyond Games, from November 15 - November 19, 2021, which will examine critical topics such as NFTs, blockchain gaming, and the metaverse. The Pocket Gamer community includes avid mobile gamers, developers, and industry professionals worldwide that have attended the international conference series Pocket Gamer Connects since 2014. PGC provides an important platform for mobile gaming enthusiasts to connect, engage, and interact, while providing industry-leading expert content and discussion around the mobile gaming space. PGC has attracted top tier sponsors and industry supporters including Microsoft, Facebook Gaming, Google Play, App Annie, Unity, Jam City, and G-Star, amongst others. The PGC Digital NEXT and Beyond Games conferences are the ninth and tenth digital conferences in the PGC digital series launched by the Company in April 2020, following the interruption of live events due to the Covid-19 pandemic.

07:43 EDT NuOrion Advisors sends letter to Macy's Chairman demanding urgent board action - NuOrion Advisors, a shareholder of Macy's, announced that it has sent a letter to the Chairman of the Board demanding the formation of a Digital Special Committee to evaluate and solicit proposals: i) from private equity firms to make a strategic investment in Macys.com, ii) from EV Car manufacturing and charging companies (e.g. Tesla, Lucid, Rivian, Atom Power) to utilize ground floor and parking facilities of landmark stores, and iii) pursue the acceptance of Crypto payments. Reference Link

07:42 EDT Dyne Therapeutics announces upcoming milestones - IND submission for DYNE-251 in DMD is planned during the fourth quarter of 2021. IND submission for DYNE-101 in DM1 is anticipated in the first quarter of 2022. IND submission for DYNE-301 in facioscapulohumeral muscular dystrophy is expected in the second half of 2022.

07:41 EDT Dyne Therapeutics expects cash to fund requirements into 2H24 - Cash, cash equivalents and marketable securities were $407.5 million as of September 30, 2021, which is anticipated to fund operations into the second half of 2024.

07:40 EDT Arbutus Biopharma expects cash to fund operations into 2Q23 - Arbutus had cash, cash equivalents and investments in marketable securities totaling $151.9 million as of September 30, 2021, as compared to $123.3 million as of December 31, 2020. During the nine months ended September 30, 2021, Arbutus used $47.9 million in operating activities, which was offset by $75.4 million of net proceeds from the issuance of common shares under Arbutus's "at-the-market" offering program. The Company believes its cash, cash equivalents and investments in marketable securities of $151.9 million as of September 30, 2021 are sufficient to fund the Company's operations into the second quarter of 2023.

07:37 EDT NRG Energy sees 2022 Adjusted EBITDA $1.95B-$2.25B

07:36 EDT Adaptimmune expects cash to fund operations into early 2024 - As of September 30, 2021, Adaptimmune had cash and cash equivalents of $42.9M. The Company believes that its existing cash, cash equivalents and marketable securities, together with the upfront and exclusivity payments under the Strategic Collaboration and License Agreement with Genentech, will fund the Company's current operations into early 2024, as further detailed in the Company's Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2021, to be filed with the Securities and Exchange Commission following this earnings release.

07:29 EDT Biomerica receives notice of allowance from CPO regarding IBS patent - Biomerica announced that the Canadian Patent Office has issued a notice of allowance for Biomerica's patent application pertaining to the Company's InFoods diagnostic guided therapy platform technology that offers a novel approach in the treatment of patients suffering from Irritable Bowel Syndrome. IBS is a chronic, often debilitating, functional gastrointestinal disorder with symptoms that include abdominal pain, bloating, and altered bowel behaviors, such as constipation and/or diarrhea, or alternating between the two. This allowed patent contains claims that broadly cover a method that enables physicians to identify patient-specific foods, such as egg, shrimp, broccoli, etc., that, when removed from the patient's diet, may alleviate or improve an individual's IBS symptoms, including constipation, diarrhea, bloating, severe cramping, pain, and indigestion.

07:28 EDT TG Therapeutics expects cash to fund planned operations into 2023 - Cash, cash equivalents and investment securities were $381.4 million as of September 30, 2021, which the Company believes will be sufficient to fund the Company's planned operations into 2023.

07:26 EDT NuStar Energy sees 2021 adjusted EBITDA $685M-$715M - NuStar CFO Tom Shoaf said that after taking into account the Eastern U.S. terminals sale, NuStar expects its 2021 adjusted EBITDA to be in the range of $685M-$715M, which is slightly higher than previous expectations. "We also expect to spend $140M-$160M on strategic capital and $35M-$45M on reliability capital in 2021. Based on these projections, we continue to target our year-end debt-to-EBITDA ratio to be below 4.0 times. And we will be achieving these solid results while generating internal cash flows to meet all of our spending needs," said Shoaf.

07:25 EDT The Tile Shop declares special dividend of 65c per share - The Board of Directors has declared a special dividend of $0.65 per common share. The dividend is payable on December 3, 2021 to shareholders of record at the close of business on November 19, 2021.

07:24 EDT The Buckle reports October net sales $96.5M, up 23.6%, SSS up 23.3% - The Buckle announced that comparable store net sales, for stores open at least one year, for the 4-week period ended October 30, 2021 increased 23.3 percent from comparable store net sales for the 4-week period ended October 31, 2020. Net sales for the 4-week fiscal month ended October 30, 2021 increased 23.6 percent to $96.5 million from net sales of $78.1 million for the prior year 4-week fiscal month ended October 31, 2020. Comparable store net sales for the 13-week third quarter ended October 30, 2021 increased 27.3 percent from comparable store net sales for the 13-week period ended October 31, 2020. Net sales for the 13-week fiscal quarter ended October 30, 2021 increased 27.3 percent to $319.4 million from net sales of $251.0 million for the prior year 13-week fiscal quarter ended October 31, 2020.

07:23 EDT Athenex announces key upcoming milestones - ANCHOR Phase 1 poster presentation at 2021; ASH in December Results from the I-SPY 2 trial of oral paclitaxel plus anti PD-1 expected in 2022; Almirall to continue phased roll-out of Klisyri in other European countries in 2022

07:21 EDT Passage Bio announces anticipated upcoming milestones - Report initial safety and 30-day biomarker data from cohort one of Imagine-1 global Phase 1/2 PBGM01 trial in 4Q21; Dose first participant in upliFT-D Phase 1/2 FTD-GRN trial in 4Q21; report initial safety and 30-day biomarker data for cohort one in 1H22; Dose first participant in GALax-C Phase 1/2 Krabbe trial in 4Q21; report initial safety and 30-day biomarker data for cohort one in 1H22; Continue to advance preclinical programs for PBML04, PBLA05 and PBCM06, and an undisclosed adult CNS program; and Continue to advance target identification research programs for Alzheimer's Disease and Temporal Lobe Epilepsy.

07:16 EDT Cars.com to acquire CreditIQ for $30M - Cars.com announces it has signed a definitive agreement to acquire CreditIQ, an automotive fintech platform that provides instant online loan screening and approvals to facilitate online car buying. Consideration for the transaction will be $30M at closing, funded using cash on hand, with the potential for up to an additional $50M in performance-based cash consideration to be earned over the next three years. The transaction is expected to close this month.

07:09 EDT Papa John's announces $425M share repurchase pact - Subsequent to the end of the third quarter, on October 28, our Board of Directors approved a new share repurchase program for up to $425.0 million of the company's common stock, which will be funded by our operating cash flows and increased liquidity following the senior notes offering and refinancing of our revolving credit facility, to further enhance shareholder returns as we also continue to invest in our long-term growth. This additional program represents approximately 9.4% of the company's currently outstanding common stock based on the closing stock price as of October 29, 2021. The new share repurchase program has an indefinite duration and will initially operate alongside the Company's existing $75.0 million share repurchase authorization, which expires on December 26, 2021.

07:06 EDT ViacomCBS: Quarterly global streaming revenue surpassed $1B - ViacomCBS said it added 4.3M global streaming subscribers to reach nearly 47M in the quarter, achieving 79% y/y growth in streaming subscription revenue.

07:04 EDT Fulcrum Therapeutics provides upcoming milestones - Initiate enrollment in a Phase 1b clinical trial of FTX-6058 in people with sickle cell disease by year-end 2021; Submit an investigational new drug application for FTX-6058 in non-sickle cell disease hemoglobinopathies, including beta thalassemia, by year-end 2021; Report an update from the ongoing Phase 1 trial of FTX-6058, including data from the 20mg and 30mg multiple-ascending dose cohorts in healthy volunteers, by year-end 2021. In conjunction with the update, report new data for FTX-6058 further elucidating the relationship between EED inhibition and HBG mRNA induction; Meet with health authorities, including the U.S. Food and Drug Administration, on losmapimod in facioscapulohumeral muscular dystrophy by year-end 2021 and provide an update on losmapimod in the first quarter of 2022; Report initial data from the Phase 1b trial of FTX-6058 in people with sickle cell disease in the second quarter of 2022; and Submit an additional IND from our portfolio by the first quarter of 2023.

06:53 EDT Roche announces repurchase of equity stake held by Novartis in Roche - Roche (RHHBY) and Novartis (NVS) have announced that they agreed on a repurchase by Roche of the 53.3M Roche shares held by Novartis. The aggregate transaction value is approx. CHF 19B. The price per share is CHF 356.9341. It corresponds to the volume weighted average price of the Roche non-voting equity certificates over the last 20 trading days up to and including November 2, Roche stated. The board of directors of Roche has approved the envisaged repurchase, which will be debt-financed by Roche. All shareholders and holders of non-voting equity certificates of Roche benefit from the earnings accretion resulting from the transaction. The transaction does not result in a change of control, as the pool formed by shareholders of the founding families has held the majority of the votes represented at general meetings of Roche previously. The voting power of the family pool will increase to approx. 67.5% upon completion of the transaction without any involvement or participation of the family pool in the transaction. The representatives of the family pool did not participate in the deliberations and the vote of the board of directors on this transaction. Based on a request of the family pool, the Swiss Takeover Board has exempted the pool from the obligation to submit a mandatory offer based on the applicable statutory provisions. The percentage of shares held by the public, or so-called "free float," will increase from currently 16.6% to 24.9% with the cancellation of the equity stake held by Novartis. This will allow the shares to be included in the Swiss Performance Index and possibly in other indices. Christoph Franz, Chairman of the Board of Directors of Roche: "I am convinced that the envisaged transaction is in the best interest of Roche and the holders of Roche equity securities from a strategic and economic perspective. As a result, Roche will be even better positioned strategically in the future to provide life-saving medicines and diagnostics to people around the world."

06:51 EDT Nintendo lowers Switch sales forecast amid global chip shortage - The company said: "For Nintendo Switch hardware, we reduced our forecast by 1.50 million units to 24.00 million units. Our shipment forecast for the second half was reduced because of the change in our production plan due to the effects of the global semiconductor shortage. On the other hand, we revised the Nintendo Switch software forecast up by 10.00 million units to 200.00 million units based on the sales performance of the first half."

06:48 EDT Regeneron sees FY21 capital expenditures $545M-$575M - Sees FY21 effective tax rate 14%-15%. Sees FY21 gross margin 88%.

06:42 EDT Merck announces U.K.'s MHRA has granted authorization for molnupiravir - Merck and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, has granted authorization in the United Kingdom for molnupiravir, which it calls "the first oral antiviral medicine authorized" for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness. In the U.K., LAGEVRIO is the planned trademark for molnupiravir; the trademark for molnupiravir in other countries has not been approved. Merck announced its application with the U.S. Food and Drug Administration for Emergency Use Authorization of molnupiravir is under review and recently announced the European Medicines Agency has initiated a rolling review of the company's Marketing Authorization Application. Merck is actively working to submit applications to other regulatory agencies around the world, it noted.

06:39 EDT Toyota plans to buy back Y150B of common stock through March 31

06:34 EDT AmerisourceBergen sees FY22 adjusted free cash flow $2B-$2.5B - Sees FY22 CapEx in $500M range; Adjusted effective tax rate to be approximately 21%-22%.

06:30 EDT Credit Suisse plans to exit prime services business - Credit Suisse said: "We plan to exit our prime services business, with the exception of Index Access and APAC Delta One, reduce the long-duration structured derivatives book, exit certain non-core GTS markets without a wealth management nexus, and optimize corporate lending exposures."

06:27 EDT Credit Suisse sees further reduction in market volumes for rest of 2021 - The company said: "Overall, we expect to see a further reduction in market volumes for the remainder of 2021 as the trading environment normalizes compared to the elevated levels seen in 2020, particularly as central banks begin to signal the end of the monetary support provided during the COVID-19 crisis. In Wealth Management, we expect recurring commissions and fees to continue to benefit from higher levels of AuM as well as increased levels of mandate penetration. With regard to transaction-based revenues in Wealth Management and the Investment Bank, we would expect revenue performance to reflect the normalization of trading conditions as well as the usual seasonal slowdown in market activity. The exit from the majority of Prime Services6 is expected to also reduce Equity Sales & Trading revenues. We would, though, expect our capital markets and advisory revenues to continue to benefit from the strong pipelines in both ECM and M&A. As noted in our strategy update, we expect an impairment in 4Q21 of ~CHF 1.6 bn in respect of the remaining Investment Bank-related goodwill on our balance sheet, which primarily relates to the Donaldson, Lufkin & Jenrette acquisition in 2000, as a consequence of which we would expect to report a net loss in 4Q21. It should be noted that this is a non-cash charge, which will neither reduce the Group's capital ratios, nor its tangible book value. As we noted at the end of 1Q21, we would expect the effective tax rate to remain significantly elevated for the final quarter of the year."

06:12 EDT Dine Brands still sees 2021 CapEx $19M - CapEx guidance includes $7M related to the restaurants segment. Still sees 2021 consolidated adjusted EBITDA $245M/$250M.

06:07 EDT Genetron's Multi-Gene Mutation Detection Kit obtains CE mark - Genetron's proprietary large-panel product, Onco PanScan - Mutation Detection Kit for Human Multi-Genes -, has obtained the CE mark, a compulsory certification mark required for marketing and distribution in the European Union. Onco PanScan is Genetron's comprehensive genomic profiling test, and is based on hybridization capture and next-generation sequencing technology. The detection kit covers more than 800 genes that are recommended by international treatment guidelines. Aside from Onco PanScan, the company's TERT and IDH1 assays along with 8-Gene Lung Cancer Assay have all been approved in China and have received the CE Marks.

06:02 EDT Becton Dickinson announces new 10M share repurchase program - The board has also authorized the company to repurchase up to 10M shares of BD common stock. This new authorization is in addition to the approximately 750,000 shares that remain available under the board's previous authorization in 2013.

05:54 EDT Volaris reports October traffic up 22% - Volaris reported its October 2021 preliminary traffic results. In October 2021, passenger demand, or RPMs, in the domestic Mexican and international markets for Volaris increased 26.2% and 23.9%, respectively, as compared to October 2019. The company capitalized on the strong market demand to add capacity, or ASMs, both domestically, up 24.9% and internationally, up 24.7%, while maintaining a high load factor of 86.3%. In October, Volaris transported 2.3M passengers, 22% higher than the pre-pandemic levels. Commenting on October traffic figures, Volaris' President and CEO Enrique Beltranena said: "We are encouraged by the demand growth in core leisure and VFR markets and are responding with the appropriate levels of capacity to match such demand."

05:37 EDT ICL sees FY21 adjusted EBITDA $1.45B-$1.5B - The company said, "Due to another quarter of strong results and continuing improvements in market conditions, ICL is raising its expectations for full year adjusted EBITDA to a range of $1,450 million to $1,500 million."

05:26 EDT Autoliv, Piaggio Group collaborate to develop airbag for powered two-wheelers - Autoliv and the Piaggio Group, a manufacturer of scooters and motorcycles, are collaborating to develop an airbag for powered two-wheelers. A joint development agreement was signed by the two parties for the purpose of developing airbags to provide greater protection for two-wheeler riders. The airbags will be mounted on the vehicle frame and will deploy in milliseconds. The popularity of powered two-wheelers continues to rise, due to widespread urbanization and urban densification and to the practicality and ease of use of powered two-wheelers.

05:22 EDT TradeStation to become public through Quantum FinTech business combination - TradeStation and Quantum FinTech (QFTA), a special purpose acquisition company, announced that they have executed a definitive business combination agreement through which TradeStation will become a publicly traded, NYSE-listed company under the ticker symbol (TRDE). The transaction is expected to close in the first half of 2022. Net proceeds from the transaction are intended to be used to help fund the company's plans to accelerate account and revenue growth through substantially increased brand-awareness and performance-based marketing spend, as well as increased product development and IT headcount for completion of certain new product feature initiatives, and to add liquidity to support an anticipated larger customer base. TradeStation's management team, including John Bartleman, president, CEO and member of TradeStation's board of directors, will continue to lead the company following completion of the transaction. Assuming no redemptions of any public shares of Quantum FinTech, the transaction will provide approximately $316M of cash prior to payment of expenses, consisting of the contribution of approximately $201M of cash held in Quantum FinTech's trust account, and $115M of additional capital through a private placement of common stock by Quantum FinTech, or PIPE. The PIPE includes, as co-anchor investments, $50M from Monex and $50M from Galaxy Digital LP. The transaction values the combined company at an implied pro forma enterprise value of approximately $1.43B. The transaction has been approved by the boards of directors of both TradeStation and Quantum FinTech, as well as by Monex, TradeStation's sole shareholder. The transaction is expected to close in the first half of 2022, subject to the satisfaction of customary closing conditions, including the approval of Quantum Fintech's shareholders. At closing, 48% of the shares held by Quantum Fintech's sponsors will convert to unvested performance-based earn-out shares or be forfeited. The structure of the business combination involves a merger between a newly-formed subsidiary of TradeStation and Quantum FinTech, with Quantum FinTech surviving the merger and becoming a wholly-owned subsidiary of TradeStation. Quantum FinTech's shareholders, including the PIPE investors, will receive shares in TradeStation in exchange for their Quantum FinTech shares. Each Quantum FinTech share held by the PIPE investors and the sponsors of Quantum FinTech will be exchanged for one common share of TradeStation. However, each holder of a Quantum FinTech public share that has elected not to redeem will receive more than one common share of TradeStation based on an exchange ratio formula supported by the issuance of an additional 750,000 shares of TradeStation common stock. More specifically, the holders of Quantum FinTech public shares will receive in exchange for each share they have elected not to redeem a number of shares of TradeStation common stock equal to the sum of the total number of non-redeemed Quantum FinTech public shares and 750,000, divided by the total number of non-redeemed Quantum FinTech public shares. Upon closing of the merger, each issued and outstanding Quantum FinTech warrant will become a warrant to receive the number of shares of TradeStation common stock that the warrant holder would have received if the holder had exercised such warrant immediately prior to the transaction. Assuming no redemptions of Quantum FinTech public shares, Monex will own approximately 80% of TradeStation at closing. All of Monex's shares in TradeStation, excluding only the shares it will acquire in the PIPE, are subject to lockups: one-third until the earlier of the first anniversary of the closing and TradeStation achieving a $12.50 per share sustained stock price, one-third until the earlier of the second anniversary of closing and TradeStation achieving a $15.00 per share sustained stock price, and one-third until the earlier of the third anniversary of closing and TradeStation achieving a $17.50 per share sustained stock price.

05:13 EDT UMC reports October sales NT$19.16M, up 25.36%